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ABSTRACT AND KEYWORDS
Autism spectrum disorders (ASD) are a cluster of neurodevelopmental disorders 
characterized by abnormal social interactions, communication deficits, and repetitive 
and restricted behaviours. Propionic acid (PPA), a component of fatty acid metabolism, 
is endogenous to the human body, produced by enteric gut bacteria, and crosses both the 
gut-blood and the blood-brain barrier. Previous research has demonstrated that repeated 
intracerebroventricular (ICV) infusions of PPA in adult rats produce behavioural and 
neuropathological changes similar to those seen in ASD patients. The current studies 
further characterized this animal model, focusing on repetitive and perseverative 
behaviours, through the use of the hole-board apparatus. Adult male Long-Evans rats 
received ICV infusions twice a day, 4 hours apart, of high-dose PPA (0.26 M), low-dose 
PPA (0.052 M), or phosphate buffered saline (PBS) for 7 consecutive days. Locomotor 
activity and nose poke behaviour were recorded daily in an automated open field 
apparatus (Versamax) equipped with a 16 well hole-board for 30 minutes immediately 
after the second infusion. In the first study, all wells remained empty. PPA treatment 
increased locomotor and nose poking behaviour in a dose-dependent manner. In the 
second study, relevant olfactory stimuli (i.e., clean and soiled bedding) was placed 
within the wells as a means of measuring perseverative behaviour. Both high- and low- 
dose PPA animals failed to modify their nose poking patterns, suggestive of 
perseverative behaviour. This work further supports the face validity of the PPA rodent 
model of ASD by demonstrating that repetitive and perseverative behaviours, core 
symptoms of autism, occur within PPA infused rats.
in
Keywords: autism spectrum disorder, hole-board apparatus, locomotor activity, 
perseveration, propionic acid, repetitive behaviour
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1.1 Autism Spectrum Disorders
Autism spectrum disorders (ASD) are a heterogeneous family of 
neurodevelopmental disorders characterized by three core symptom domains: deficits in 
communication, abnormal social interaction, and restricted and/or repetitive interests 
and behaviours (American Psychiatry Association, 1994). Other symptoms include 
hyperactivity, sensitivity to sensory stimuli, resistance to change, and cognitive deficits 
in attention or memory (Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, & 
Markram, 2007; Murray, 2010; Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 
2008). Furthermore, autism often co-exists with a variety of other conditions, including 
fragile X syndrome, tuberous sclerosis, mental retardation, and epilepsy (Muhle, 
Trentacoste, & Rapin, 2004; Tuchman, Moshe, & Rapin, 2009). Typically, autistic 
symptoms become evident in children before 36 months of age (Rapin, 1997). Most 
children who develop autism have early onset symptoms within the first year of life 
characterized by abnormal social development (e.g., deficits in social smiling and eye 
contact), delay in babbling, poor motor coordination, and repetitive motor actions 
(Barbara & Dissanayake, 2009; Landa, 2008). About one-third of cases are considered 
late onset. Children appear to develop normally until about 2 years of age, at which 
point social and communication skills regress to that of an autistic phenotype (Ozonoff, 
Williams, & Landa, 2005)
Over the last decade, there has been nearly a 300% increase in the prevalence of 
autism, with current estimates of approximately 1 in every 110 children affected with 
autism, and males are four times more likely to be affected than females (Boyle et al., 
2011). Although the significant increase in ASD is at least partly due to better awareness
and broadening diagnostic criteria, it is unlikely that this can solely account for the 
substantial increased prevalence of autism. In fact, several recent studies have provided 
support for a true increase in disease frequency over the last several decades, unrelated 
to changes in diagnostic criteria (Blaxill, 2004; Schechter & Grether, 2008). The rising 
incidence of autism is a matter of urgent public concern. Unfortunately, the etiology of 
autism is poorly understood and researchers do not fully understand the contributions of 
genetics, biology, and the environment to the pathogenesis and on-going 
symptomatology of ASD. Thus, it is imperative that research examines the mechanisms 
behind autism in order to better understand this complex disease. An effective way to 
accomplish this is to develop an animal model. Animal models allow researchers to 
examine the underlying mechanism/cause of a disease in a controlled manner that is 
ethically impossible to do in humans. The major purpose of the current studies is to 
provide further support for a rodent model of autism developed in our laboratory as a 
means of furthering our understanding of the underlying pathophysiology of ASD.
1.1.1 Genetic and Environmental Aspects of ASD
Evidence from family and twin studies suggests a moderate to strong genetic 
basis for ASD susceptibility. The reported heritability estimate for autism is as high as 
90%, with a significantly higher concordance rate in monozygotic twins than dizygotic 
twins (Bailey et al., 1995; Elallmayer et al., 2011). Moreover, there is a high recurrence 
rate of autism such that in families with at least one case of ASD, the prevalence of 
autism within the family is 100 times higher than the general population (Rutter,
Silberg, O'Connor, & Simonoff, 1999). Autism is considered biologically and 
phenotypically heterogeneous, and this variability is also apparent in genetic linkage
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studies which show numerous candidate genes in ASD populations (Geschwind, 2011). 
Unfortunately, there is no single mutation attributed to causing ASD and no genes that 
can serve as definitive biomarkers for the disorder (Scherer & Dawson, 2011). Thus, 
there is a general agreement in the literature that ASD has a large genetic component, 
but further research is required to translate genomic linkage discoveries into diagnostics 
relevant for prevention and treatment.
Because genetics cannot fully account for the manifestation of autism, 
researchers have become increasingly interested in environmental agents that may act 
during critical developmental periods. Chemical toxins and infectious agents present in 
the environment during prenatal and early postnatal periods have been implicated in the 
pathogenesis o f ASD. For instance, children exposed to thalidomide, valproic acid, and 
ethanol in utero have an increased risk of ASD (Ratajczak, 2011). Maternal infections 
have also been identified as a risk factor for autism, with approximately 43% of mothers 
with an autistic child experiencing a respiratory, urinary, or other infection during 
pregnancy as compared to 26% of control mothers (Comi, Zimmerman, Frye, Law, & 
Peeden, 1999). Fever, a common physiological response to infection, may be treated 
with anti-pyretics, such as acetaminophen, during pregnancy. Anti-pyretics interfere 
with normal immunological development in the brain, and may partially explain why 
maternal infection during pregnancy leads to increased susceptibility to ASD in 
offspring (Currenti, 2010). Maternal stress, maternal anti-bodies, heavy metals, 
phthalates, organophosphate pesticides, and many other environmental factors are also 
believed to play a role in the etiology of ASD (Ratajczak, 2011; Ronald, Pennell, & 
Whitehouse, 2010). Although previously thought to be a causal environmental factor in
4
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ASD, numerous studies have failed to support a relationship between the mumps- 
measles-rubella (MMR) vaccine and autism (Honda, Shimizu, & Rutter, 2005; Homig et 
al., 2008; Schultz et ah, 2008). It is likely that an interaction between genetic 
predisposition and environmental factors results in the manifestation and severity of 
ASD. Indeed, a growing number of environmentally responsive genes and pathways are 
being identified in some autistic populations (Fatemi, 2008; Herbert, 2010)
1.1.2 Central Nervous System and Systemic Abnormalities in ASD
Although autism has been traditionally considered a strongly brain-based 
disorder, emerging findings support the idea of ASD as a systemic disorder involving 
immune and metabolic dysfunction that also affects the central nervous system (CNS) 
(Chauhan & Chauhan, 2006; Herbert, 2005a). In particular, there is increasing evidence 
for the role of oxidative stress, antioxidant impairment, and chronic inflammatory 
processes in ASD from childhood through adulthood (Anderson, Hooker, & Herbert, 
2008). Recent studies of post-mortem brain tissue in patients with ASD revealed innate 
neuroinflammatory changes characterized by reactive astrogliosis and activated 
microglia in the cerebral cortex, white matter, and cerebellum (Morgan et ah, 2010; 
Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005). Cytokine protein arrays 
also demonstrated elevations in proinflammatory cytokines , such as interleukin-6 (IL- 
6), in both the brain tissue and cerebrospinal fluid of autistics. Interestingly, these 
neuroinflammatory changes were observed in both adults and children with the disorder, 
suggesting that neuroinflammation may be a permanent state of pathology in ASD that 
starts early. This immune dysfunction may be a potential mechanism for the 
pathogenesis of autism, given that glial cells are important in developing and mature
nervous systems via their role in immune function, support of neurons, the integrity of 
the blood-brain barrier (BBB), and myelination of neurons (Barron, 1995).
Besides an innate neuroinflammatory response and increased cytokines, other 
CNS abnormalities have also been found in persons with ASD. Imaging and post­
mortem studies have demonstrated that the brain of autistics is grossly normal, but other 
subtle anatomic aberrations do exist (Bauman & Kemper, 2005). Young children with 
autism (but not older) have unusually large brain volumes due to an overgrowth shortly 
after birth followed by slowed growth a few years later (Herbert, 2005b). Compared to 
controls, autistic brains show smaller neuronal cell size and increased cell packing 
density in the limbic system (e.g. hippocampus and amygdala), a pattern consistent with 
truncated development (Palmen, van Engeland, Hof, & Schmitz, 2004). Purkinje cell 
size in the cerebellum has been shown to be consistently reduced in brain tissue of ASD 
patients at autopsy (Fatemi et al., 2002). Additionally, elevated 3-nitrotyrosine levels (a 
specific marker of oxidative damage to proteins), has been documented in cerebellar 
tissue in autism (Sajdel-Sulkowska, Lipinski, Windom, Audhya, & McGinnis, 2008). 
Imaging studies of autistics have also shown an overall increase in white matter 
thickness, suggestive of an underlying glial dysfunction, as well as a widespread 
reduction in the functional connectivity among brain regions (Hughes, 2007; Sokol & 
Edwards-Brown, 2004; Stigler, McDonald, Anand, Saykin, & McDougle, 2011).
Various systemic abnormalities indicative of altered immune regulation and 
oxidative stress have also been observed in autism. An association between ASD and 
immune dysfunction has been supported by reports of increased incidence of
6
autoimmune disease in families with an autistic child and altered metabolism in immune
cells in children diagnosed with ASD (Atladottir et al., 2009; Suh, Walsh, McGinnis, 
Lewis, & Ames, 2008). Furthermore, analysis of plasma samples from autistic children, 
as compared to controls, have shown elevated production of brain-derived neurotrophic 
factor (BDNF) and tumour necrosis factor alpha (TNF-a) by peripheral immune cells 
under mitogenic stimulation, suggestive of an excessive innate immune response 
(Enstrom et al., 2008; Jyonouchi, Sun, & Le, 2001). Oxidative stress has also been 
implicated in ASD pathogenesis. At a cellular level, oxidative stress occurs when the 
levels of deleterious reactive oxygen species exceed the antioxidant and detoxification 
capabilities of that cell, which can result in mitochondrial dysfunction, abnormal 
membrane lipids, inflammation, and DNA damage (Pardo & Eberhart, 2007). Indeed, 
increased oxidative stress has been observed in autism, as demonstrated by increased 
lipid peroxidation and decreased antioxidant proteins (e.g., glutathione and transferrin) 
in the plasma of children with autism (Chauhan, Chauhan, Brown, & Cohen, 2004; 
James et al., 2006). Recent evidence has also suggested a role for metabolic dysfunction 
in autism involving disordered fatty acid profiles and altered energy dynamics of the 
mitochondria (Gargus & Imtiaz, 2008; Wiest, German, Flarvey, Watkins, & Hertz- 
Picciotto, 2009).
1.1.3 Gastrointestinal Factors of ASD
Although a gastrointestinal (GI) pathology specific and unique to autism has not 
been identified, there appears to be a high degree of comorbidity between 
gastrointestinal disorders and ASD (Buie et al., 2010). A number of GI symptoms and/or 
disorders have been reported in ASD patients, including diarrhea, abdominal pain, 
constipation, bloating, gastroesophageal reflux, gastritis, inflammatory bowel disease,
7
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and celiac disease, among others (Bauman, 2010). Dietary factors are also associated 
with the behavioural symptoms of ASD. Parents frequently report an increase in the 
severity of autistic symptoms in their child following the consumption of refined wheat 
and dairy products, and an improvement in symptoms following the implementation of a 
casein- and gluten-free diet (Jyonouchi, 2009). In support of these anecdotal reports, a 
recent randomized controlled trial showed improvements in attention and reduced 
hyperactivity in children with ASD after a gluten- and casein-free dietary intervention 
(Whiteley et ah, 2010). Moreover, some children with ASD have intestinal lesions, 
increased intestinal permeability, and pro-inflammatory cytokine responses against 
dietary proteins similar (but not identical) to those observed in patients with known 
dietary protein intolerance/allergy (de Magistris et al., 2010; Jyonouchi, Sun, & Itokazu, 
2002; White, 2003).
The human intestinal tract contains an enormous microbial ecosystem, or gut 
microbiota, that is partially responsible for maintaining human health via protective, 
structural, and metabolic roles (Prakash, Rodes, Coussa-Charley, & Tomaro- 
Duchesneau, 2011). Disruption of the normal gut microbiota has been associated with 
various disease processes, including autoimmune and metabolic disorders (Mai & 
Draganov, 2009). Analysis of stool specimens from autistic children with co-morbid GI 
symptoms has shown evidence of abnormal gut microflora, particularly a greater 
diversity and number of clostridial species (Finegold et al., 2002; Parracho, Bingham, 
Gibson, & McCartney, 2005; Song, Liu, & Finegold, 2004). Another enteric organism, 
Desulfovibrio, has also been shown to be more common in regressive cases of autism 
(Finegold, 2011). Colonization with clostridial or other species may be facilitated by
9
antibiotic use, which can disrupt the indigenous gut species and promote the overgrowth 
of antibiotic resistant pathogenic organisms (as is the case with both Clostridium and 
Desulfovibrio). Indeed, a retrospective study by Niehus and Lord (2006) found that the 
early medical history of children with ASD included significantly more antibiotic use 
than typically developing children. Recent evidence from studies in rodents has shown 
that gut microbiota can modulate brain development and behaviour (Heijtz et al., 2011; 
Li, Dowd, Scurlock, Acosta-Martinez, & Lyte, 2009). Abnormal gut microflora may 
contribute to the pathogenesis of ASD in genetically sensitive subpopulations.
1.2. Propionic Acid
Propionic acid (PPA) is a component of fatty acid metabolism, and like other 
short-chain fatty acids (SCFA), such as acetic and butyric acid, PPA is a metabolite of 
microbial fermentation of undigested food in the colon (Al-Lahham, Peppelenbosch, 
Roelofsen, Vonk, & Venema, 2010). Besides gut bacterial production, which contributes 
to about 20% of PPA sources in the body, PPA is also produced as a result of amino 
acid (~50%) and odd-chain fatty acid (-30%) catabolism (Thompson et al., 1990). 
SCFAs comprise a significant metabolic energy source, and the metabolism of PPA, via 
a series of steps, results in succinyl-CoA which can be incorporated directly into the 
Krebs cycle (Al-Lahham et al., 2010). Certain families of enteric bacteria, including 
propionibacteria and clostridia, are known to produce PPA (Femandez-Garcia & 
McGregor, 1994; Finegold, Song, & Liu, 2002). In addition to these endogenous 
sources, PPA is present in some food products that use bacterial fermentation in the 
manufacturing process (e.g. dairy products, such as cheese and yogurt) and is commonly 
used as a food preservative due to its anti-fungal properties (Brock & Buckel, 2004).
However, it is important to note that these food sources contribute to only a small 
proportion of total PPA in the human circulation due to the large quantities produced by 
bacterial fermentation in the gut (Cummings, Pomare, Branch, Naylor, & Macfarlane, 
1987).
PPA has direct physiological effects on the GI tract, including altering gut 
motility, increasing the contraction of colonic smooth muscle, dilating colonic arteries, 
and activating mast cells (Karaki et al., 2006; Mitsui, Ono, Karaki, & Kuwahara, 2005). 
As a weak organic acid, PPA can readily cross both the gut-blood and blood-brain 
barriers passively or actively via monocarboxylate transporters where it can cross cell 
membranes and accumulate within cells (Bergersen, Rafiki, & Ottersen, 2002). PPA is 
capable of inducing widespread effects in the CNS, and can inhibit Na+/K+ ATPase, 
increase NMDA receptor sensitivity, alter mitochondrial and fatty acid metabolism, and 
affect immune activation and gene expression (Brass & Beyerinck, 1988; de Mattos- 
Dutra et al., 2000; Parab, Nankova, & La Gamma, 2007; Wajner, Latini, Wyse, & 
Dutra-Filho, 2004; Wyse et al., 1998). Furthermore, PPA can concentrate within cells, 
resulting in intracellular acidification, which can alter neurotransmitter release, inhibit 
gap junctions, and promote intracellular calcium release, all of which can potentially 
affect neuronal communication and behaviour (Remblier, Pontcharraud, Tallineau, 
Piriou, & Huguet, 1999; Rorig, Klausa, & Sutor, 1996). Given the diverse physiological 
effects on the GI tract and CNS, PPA may be a putative link between the dietary, GI, 
and behavioural symptoms of ASD in genetically susceptible subpopulations.
Several findings suggest that PPA may be associated with the etiology and 
pathogenesis of ASD. Propionic acidemia is a genetically acquired metabolic disorder
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which results in an accumulation of PPA caused by a deficiency of the mitochondrial 
enzyme propionyl-coenzyme A carboxylase (Hofherr et al., 2009). Symptoms of 
propionic acidemia include vomiting, loss of appetite, and motor, social, and language 
delay, all o f which are reminiscent of autistic symptoms (Kaya et ah, 2008). In addition, 
exposure to valproic acid may lead to increased levels of SCFAs such as PPA, and 
valproic acid exposure early in development increases the likelihood of ASD (Omoy, 
2009). As previously mentioned, some children with autism, particularly those with GI 
symptoms and behavioural regression, have increased levels of enteric Clostridium and 
Desulfovibrio, both of which are known to increase levels of PPA and other SCFAs 
(Finegold, 2011). Additionally, serum studies from autistic patients have shown 
metabolic dysfunction consistent with PPA’s physiological effects, such as impairments 
of glutathione and carnitine metabolism (Filipek, Juranek, Nguyen, Cummings, & 
Gargus, 2004; James et ah, 2006).
The properties of PPA led our laboratory to propose that alteration of PPA levels 
or metabolism may be related to ASD, and therefore we recently investigated the effects 
of exposure to PPA in rodents as a potential novel animal model of ASD. Repeated, 
central infusions of PPA in adult rats produced behavioural, biochemical, 
electrophysiological, and neuropathological effects similar to those seen in human cases 
of autism (MacFabe et ah, 2007, 2008). We found that intracerebroventricular (ICV) 
infusions of PPA in adult rats induced repetitive behaviours, kindled seizures, 
hyperactivity, turning behaviour, and retropulsion, all of which bear resemblance to 
symptoms seen in ASD (MacFabe et ah, 2007, 2008). Immunohistochemical analyses of 
brain tissue in PPA-infused rodents revealed an innate neuroinflammatory response
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characterized by reactive astrogliosis and activated microglia, as well as increased 
oxidative stress and decreased glutathione, in the absence of any apoptotic cell loss 
(MacFabe et al., 2007, 2008), which is consistent with autopsy studies of human autistic 
patients (Bauman & Kemper, 2005; Vargas et ah, 2005). Furthermore, analysis of brain 
lipid composition in PPA-infused rodents reveals altered phospholipid and acylcamitine 
profiles similar to the abnormal lipid profiles seen in erythrocytes and plasma of autistic 
patients (Bell et ah, 2004; Thomas et ah, 2010)
Another set of studies found that central administration of PPA resulted in social, 
cognitive, and sensorimotor impairments (Shultz et ah, 2008, 2009), lending further 
credence to the face validity of the PPA rodent model. Given the developmental and 
systemic nature of ASD, more recent work in our laboratory using the rodent model has 
evaluated both central and systemic effects of PPA in adolescent and neonatal rats. Thus 
far, our results have been consistent with symptoms observed in autistic patients, such as 
object fixation in adolescent rats reminiscent of the restricted interests in ASD (for 
review see Foley, Tichenoff, Ossenkopp, & MacFabe, 2010; MacFabe, Cain, Boon, 
Ossenkopp, & Cain, 2011; Shams, Kavaliers, Foley, Ossenkopp, & MacFabe, 2009). 
Finally, deuterium tracing of PPA in rat brain has allowed our laboratory to confirm 
PPA associated oxidative stress and edema (Nie et ah, 2011). Taken altogether, these 
findings suggest that alterations in PPA metabolism may play a significant role in the 





One of the core symptom domains of ASD is the presence of stereotyped or 
repetitive/restrictive behaviours (American Psychiatry Association, 1994). These 
behaviours typically occur with high frequency and persist across the lifespan, at higher 
rates and intensities than any other developmental disability (Esbensen, Seltzer, Lam, & 
Bodfish, 2009; Matson, Dempsey, & Fodstad, 2009). Repetitive behaviour in ASD may 
include motor stereotypies (e.g., hand flapping or body rocking), verbal rituals (e.g., 
repetitive questioning), and sometimes self-injurious behaviours (McDougle, Kresch, & 
Posey, 2000; Muthugovindan & Singer, 2009). Restricted interests and resistance to 
change (or perseverative behaviours) also characterize autism and may manifest as 
inflexible adherence to routines or rituals, a limited number of interests and activities, a 
behavioural need to preserve “sameness,” or preoccupation with part of an object or 
objects (Kootz, Marinelli, & Cohen, 1982; Matson, Dempsey, & Fodstad, 2009).
Repetitive behaviours are apparent in a wide range of psychiatric disorders, 
including obsessive compulsive disorder (OCD), attention deficit hyperactivity disorder 
(ADHD) Tourette’s syndrome, and schizophrenia (Ridley, 1994), as well as in children 
suffering from sensory impairments or severe intellectual disability (Barry, Baird, 
Lascelles, Bunton, & Hedderly, 2011). Some of these disorders, such as OCD and 
ADHD, are often co-morbid with autism (Leyfer et al., 2006). Furthermore, autism 
spectrum traits have been found in children and adolescents diagnosed with OCD 
(Ivarsson & Melin, 2008), suggesting that perhaps these disorders have common 
etiologies, underlying biological mechanisms, or similarly affected brain regions.
Although several studies have shown that dysfunction in the basal ganglia, 
frontal cortex, and frontostriatal circuits are involved in the manifestation of repetitive 
and perseverative behaviours seen in many psychiatric disorders, it is important to point 
out that the repetitive and “sameness” behaviours seen in ASD are characteristically 
different from those seen in OCD (Ridley, 1994; McDougle et al., 2000). Compared to 
adults with OCD, autistic patients are more likely to engage in repetitive ordering, 
hoarding, telling or asking, tapping, and self-damaging behaviours and are less likely to 
engage in cleaning, checking, and counting behaviours that are common in patients with 
OCD (McDougle et al., 1995; Zandt, Prior, & Kyrios, 2009). Additionally, adults with 
autism had significantly more repetitive behaviours than repetitive thoughts, and no 
autistic patient had repetitive thoughts alone. Few autistic patients made an active effort 
to suppress or resist their repetitive behaviours. In contrast, nearly all patients with OCD 
had both repetitive thoughts and behaviours, only a very small percentage (~ 0.5%) had 
only repetitive behaviours, and 95% of OCD patients regarded the obsessions and 
compulsions as intrusive and actively attempted to suppress the thoughts and resist the 
behaviours.
The purpose of the current studies is to further explore the core symptom domain 
of repetitive and perseverative behaviours in ASD in the context of an animal model. 
Animal models provide an opportunity to advance our understanding of the biological 
mechanisms underlying autistic disorders (van der Staay, 2006). In order to extend the 
validity of the PPA rodent model of ASD proposed by our laboratory, it is essential to 
test the model using behavioural assays relevant to the symptoms of autism (Crawley, 
2007; MacFabe et al., 2007). One such behavioural task that is useful for assessing
14
repetitive behaviour in rodents is the hole-board apparatus (File & Wardill, 1975; 
Makanjuola, Hill, Maben, Dow, & Ashcroft, 1977; Moy et al., 2008). The hole-board 
apparatus is an elevated platform with 16 equally spaced holes (with wells underneath) 
that can be fitted into an open field chamber, allowing for measurement of both 
locomotor activity and nose pokes (the measure specific to the hole-board). Although 
not currently in widespread use as a behavioural test, research has shown that analysis of 
nose pokes within the hole-board task can provide a valid and reliable measure of 
exploratory and repetitive behaviours (File & Wardill, 1975a, 1975b). Furthermore,
Moy and colleagues (2008) demonstrated that using the hole-board task may be a useful 
method of assessing restricted and perseverative behaviours in rodents, particularly 
when relevant olfactory stimuli are placed in the hole-board.
The aims of the current studies were to:
I. Assess repetitive and perseverative behaviour following central PPA 
treatment using the hole-board task
II. Investigate the dose-response effects of PPA with a low-dose of PPA 
(0.052 M) and a high-dose of PPA (0.26 M)
Both objectives were devised to further validate the use of PPA as an effective rodent 
model of ASD. The present studies are the first to investigate the effects of PPA using 
the hole-board task, and the first to assess dose-related behavioural effects of PPA 
treatment using a low-dose of PPA not previously used and comparing it to the “high- 
dose” of PPA used in our previous experiments. Chapter 2 reports the dose-related 
effects of central administration of PPA on locomotor and nose poking behaviour in 
adult rats when all wells within the hole-board were empty. It was expected that similar
15
to previous work, PPA treatment would result in increased locomotor and repetitive 
activity in a dose-dependent manner. The experiment in Chapter 3 was designed to 
determine if placement of relevant olfactory stimuli (i.e., soiled and clean cage bedding) 
within the hole-board would alter the pattern of hole-board exploration and whether 
PPA-treated animals would adapt their behaviour in response to a change in the hole- 
board environment. Given that PPA-treated animals have shown a perseverative pattern 
of responding in the water maze task (Shultz et al., 2009), it was expected that PPA- 
treated rodents in the hole-board task would fail to adapt their behaviour and that these 
perseverative effects would be more pronounced in high-dose PPA animals than low- 
dose PPA animals. Chapter 4 provides a summary of both experiments as well as 
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Chapter 2
Intracerebroventricular propionic acid results in a dose-dependent increase in 
locomotor and nose poking behaviour in rats tested in an automated hole-board 
apparatus: Support for an animal model of autism spectrum disorders
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2.1 Introduction
Autism spectrum disorders (ASD) are a cluster of neurodevelopmental disorders 
affecting approximately 1 in 110 children, which represents a 300% increase in 
prevalence over the last decade (Boyle et ah, 2011). The three main categories of 
behavioural symptoms in ASD include impaired social interaction, communication 
deficits, and restricted/repetitive interests and behaviours (American Psychiatry 
Association, 1994). Other symptoms associated with autism include sensitivity to 
sensory stimuli, hyperactivity, resistance to change, cognitive deficits, and seizures 
(Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, & Markram, 2007; Murray, 2010; 
Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). Although there is a strong 
multigenetic basis for ASD susceptibility (Bailey et ah, 1995; Hallmayer et ah, 2011), 
recent research suggests that environmental, dietary, and gastrointestinal factors may 
play a role in the etiology and pathogenesis of autism (Ratajczak, 2011; Williams et ah, 
2011).
Several findings suggest that exposure to propionic acid (PPA), a short-chain 
fatty acid (SCFA) that is endogenous to the human body, may be associated with ASD. 
PPA is an intermediary of fatty acid metabolism and is a metabolic end-product of 
microbial fermentation in the gut (Al-Lahham, Peppelenbosch, Roelofsen, Vonk, & 
Venema, 2010; Thompson et al., 1990). Parents frequently report an increase in 
behavioural symptoms when their autistic children ingest refined wheat and dairy 
products (Jyonouchi, 2009), which contain PPA either as a result of the manufacturing 
process (e.g., dairy) or as an additive food preservative (e.g., many wheat products) 
(Brock & Buckel, 2004). Furthermore, consumption of these products can result in
increased production of PPA via bacterial fermentation of undigested food within the 
gut (Cummings, Pomare, Branch, Naylor, & Macfarlane, 1987). In support of these 
anecdotal reports from parents, a randomized controlled trial showed improvement in 
attention and reduced hyperactivity following implementation of a casein- and gluten- 
free diet in children with ASD (Whiteley et al., 2010). A subset of autistic children with 
co-morbid gastrointestinal symptoms have abnormal gut microflora, including elevated 
levels of Clostridium and Desulfovibrio, both of which are known to produce SCFAs 
such as PPA (Finegold et al., 2002; Finegold, 2011; Parracho, Bingham, Gibson, & 
McCartney, 2005). Exposure to valproic acid early in development, which can increase 
levels of PPA and other SCFAs, increases the likelihood of ASD (Omoy, 2009). 
Furthermore, serum analysis in ASD patients has shown metabolic impairment of 
glutathione, carnitine, and fatty acids consistent with the physiological effects of PPA 
(Bell et al., 2004; Filipek, Juranek, Nguyen, Cummings, & Gargus, 2004; James et al., 
2006).
PPA is a weak organic acid, and can readily cross the gut-blood barrier and gain 
access to the central nervous system (CNS) either passively across the blood-brain 
barrier or via monocarboxylate transporters (Bergersen, Rafiki, & Ottersen, 2002). PPA 
has widespread effects in the CNS including inhibition of Na+/K+ ATPase, increased 
NMDA receptor sensitivity, alteration of mitochondrial and fatty acid metabolism, 
immune activation, and changes in gene expression (Brass & Beyerinck, 1988; de 
Mattos-Dutra et al., 2000; Parab, Nankova, & La Gamma, 2007; Wajner, Latini, Wyse, 
& Dutra-Filho, 2004; Wyse et al., 1998). In addition, PPA can accumulate within cells, 
resulting in intracellular acidification which can alter neurotransmitter release, inhibit
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gap junctions, and promote intracellular calcium release, all of which can potentially 
affect neuronal communication and behaviour (Remblier, Pontcharraud, Tallineau, 
Piriou, & Huguet, 1999; Rorig, Klausa, & Sutor, 1996).
Our laboratory has proposed that alterations in PPA levels or metabolism might 
be related to ASD and that administration of PPA in rodents may be a useful animal 
model in which to further our understanding of the biological mechanisms underlying 
ASD (MacFabe et al., 2007). Repeated, central infusions of PPA in adult rats induced 
hyperactivity, repetitive behaviours, kindled seizures, social impairments, cognitive 
deficits, altered brain phospholipid profiles, increased oxidative stress, and an innate 
neuroinflammatory response (MacFabe et ah, 2007, 2008; Nie et ah, 2011; Shultz et ah, 
2008, 2009; Thomas et ah, 2010), consistent with findings from ASD patients (Bauman 
& Kemper, 2005; Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005; Wiest, 
German, Harvey, Watkins, & Hertz-Picciotto, 2009). More recent work in our 
laboratory investigating the systemic and developmental effects of PPA in adolescent 
and neonatal rats has been consistent with the symptoms seen in autistic patients and 
provides further validity to the PPA rodent model of autism (for review of these results 
see Foley, Tichenoff, Ossenkopp, & MacFabe, 2010; MacFabe, Cain, Boon, Ossenkopp, 
& Cain, 2011; Shams, Kavaliers, Foley, Ossenkopp, & MacFabe, 2009).
The current study aimed to extend previous findings of this animal model by 
examining the central effects of two doses of PPA on locomotor and repetitive 
behaviours in adult rats using the hole-board task. It was expected that PPA treatment 
would produce increased locomotor and repetitive behaviour in a dose-dependent
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Thirty-five naive male Long-Evans rats were used, weighing 200-225 g 
(approximately 47-49 days old) at the time of arrival to the facility. Animals were 
housed individually in standard rat polypropylene cages (W 26 x L 48 x H 21 cm) with 
ad libitum access to food (LabDiet RMH 3000) and tap water in a temperature- 
controlled colony room (21 ± °C) on a 12:12 h light-dark cycle (lights on at 07:00 h). 
Behavioural testing occurred during the light phase of the cycle. Animals were left 
undisturbed for one week prior to the cannulation surgery. All procedures followed the 
guidelines of the Canadian Council on Animal Care and were approved by the 
University of Western Ontario Animal Use Subcommittee.
2.2.2 Apparatus
Locomotor activity was monitored using three Versamax Animal Activity 
Monitors (AccuScan Model DCM-8, Columbus, OH, USA). Each monitor consisted of 
a clear Plexiglas open field chamber (W 40 cm x L 40 cm x H 30.5 cm) and a clear 
plastic lid with air holes. Movement was recorded via a grid of infrared beams located 
on all four sides of the chamber for horizontal activity (16 equally spaced beams 2.54 
cm apart and 4.5 cm from the floor) and a grid of infrared beams located on two sides of 
the chamber for vertical activity (16 beams located 15 cm above the box floor). The 
automated activity monitors were equipped with a hole-board on the floor of the 
chamber to measure nose poke responses (see Figure 2.1A-D). The hole-board is an
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Figure 2.1. Photographs of the automated activity monitors equipped with a hole-board 
on the floor of the chamber. (A) Side view; (B) Front view; (C) Top-down view; (D) 
Top-down view with platform removed to show the 16 equally spaced wells beneath the
floor of the chamber.
elevated platform with 16 equally spaced holes (2.54 cm diameter) with small wells 
(5.08 cm diameter) underneath each hole. A set of infrared beam sensors, separate from 
those recording locomotor activity, are located between the well and the platform, 
allowing for nose poke counts for each hole to be recorded via beam breaks. VersaMax 
Analyzer software (Accuscan Model VSA-16, Columbus, OH) recorded data from each 
automated activity monitor and relayed it to a computer that stored the data for 
subsequent analysis. All sessions within the automated activity monitors were video- 
recorded and later reviewed to ensure accuracy of the computer generated nose poke 
data.
2.2.3 Procedure
2.2.3.1 Surgery. To induce anaesthesia, animals were placed into a sealed plastic 
box into which 4% isoflurane at 2 L/min oxygen was introduced. The animal was then 
placed into a Kopf stereotaxic device equipped with a gas flow mask delivering 2.5% 
isoflurane at 500 mL/min of oxygen to maintain anaesthesia during surgery. Under 
aseptic conditions, right lateral ventricular cannulation surgery was performed (AP -1.4 
mm, ML -1.8 mm, DV -3.0 mm). Each animal was implanted with a 23-gauge guide 
cannula with the tip in the right lateral ventricle in accordance with a standard rat atlas 
(Paxinos & Watson, 1998). The indwelling cannula was secured chronically using 
dental acrylic anchored in place with small stainless steel screws inserted into the skull. 
A removable obturator sealed the guide cannula and was only removed for infusions 
during the experiment. Animals received a subcutaneous injection of analgesic 
(ketoprofen, 1 mL/kg) immediately post-operatively. After surgery, animals were kept
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warm under a heating lamp until righting responses and locomotion returned. Animals 
were housed individually and allowed two weeks recovery prior to testing.
2.2.3.2 Treatment groups and infusion procedure. Following recovery, animals 
were randomly assigned to one of three groups: high-dose PPA (0.26 M, 4.0 pL, n =
11), low-dose PPA (0.052 M, 4.0 pL, n = 9), or phosphate buffered saline vehicle (PBS, 
4.0 pL, n = 15). Propionic acid was dissolved in PBS vehicle, and all solutions were 
buffered to pH 7.5 using concentrated HCL or NaOH. Each animal received 
intracerebroventricular (ICV) infusions twice daily (separated by 4 hours) for seven 
consecutive days. The first infusion occurred during the light phase at 09:00 h. Solutions 
were infused using a 30 gauge injection cannula that was connected to a Sage syringe 
pump with sterile PE10 tubing. The tip of the injection cannula protruded 0.5 mm 
beyond the tip of the guide cannula. The syringe pump dispensed 4.0 pL of solution 
over a 60 s interval, and the injection cannula remained in place for an additional 60 s 
before being removed.
2.2.3.3 Testing. Following two weeks of recovery, rats were handled and 
habituated to the automated activity monitors for two days (30 minutes per day). On the 
third day, baseline levels of activity and nose poke responses were recorded in the 
absence o f infusion. During the seven treatment days, animals were placed in the 
automated monitors following the second infusion of the day for 30 minutes to record 
locomotor activity and nose poke counts (six 5 minute time bins). All wells within the 
hole-board platform remained empty for the entire duration of behavioural testing 
(including habituation, baseline, and testing days). Rats were weighed daily to monitor
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health.
2.2.3.4 Euthanasia. The day after behavioural testing was completed, rats were 
euthanized via either intraperitoneal injection (euthanyl 270 g/mL, ~0.5 mL per animal) 
or decapitation. Those euthanized by injection were transcardially perfused with a 
PBS/4% paraformaldehyde solution. The fixed brains were removed and kept in a 
sucrose solution for localization of the indwelling cannula. Animals that were 
decapitated were later used for a lipid analysis study. Brains were quickly removed 
following decapitation, frozen on dry ice, and stored in a -70 °C freezer until subsequent 
lipid analysis. Whole blood collected from the trunk was spun in a centrifuge at 3000 x 
g for five minutes and plasma was collected for lipid analysis.
2.2.4 Behavioural Measures
Locomotor activity was analyzed using eight distinct measures. The horizontal 
activity measures analyzed were: total distance -  total horizontal distance (cm) 
travelled; horizontal movement time -  amount of time (s) an animal was engaged in 
horizontal movement; and number of horizontal movements -  the number of horizontal 
movements separated by a 1 s stop time. The vertical activity measures analyzed were: 
vertical movement time -  amount of time (s) an animal spent in a vertical position; and 
number of vertical movements -  number of vertical movements separated by a 1 s stop 
time. The repetitive locomotor measures were: clockwise revolutions -  the numbers of 
times an animal moved around in a clockwise circle of at least 2 inches in diameter; 
counterclockwise revolutions -  the number of times an animal moved around in a 
counterclockwise circle of at least 2 inches in diameter; and the number of stereotypic 
movements -  repeated breaking of the same infrared beam separated by 1 sec or more.
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Nose poke behaviour was analyzed using total nose poke counts and hole 
category. Total nose poke counts are the total number of nose pokes across an entire 
testing session (includes all 16 different holes in the hole-board). Hole category data 
classified the holes into three categories based on location within the open-field 
apparatus in order to determine if there was a pattern of hole preference. The three hole 
categories based on location included comer holes (1, 4, 13, and 16); centre holes (6, 7, 
10, and 11), and wall holes (2, 3, 5, 8, 9, 12, 14, and 15) (see Figure 2.2). In order to 
control for differences in total nose pokes, each hole category was calculated as a 
percent of total nose pokes for each rat (e.g., centre hole nose pokes divided by total 
number of nose pokes multiplied by 100).
2.2.5 Statistical Analysis
Data were analyzed for main effects and interactions using a repeated measures 
split-plot analysis of variance (ANOVA) with drug treatment (PBS, low-dose PPA, and 
high-dose PPA) as the between-subjects factor and infusion day (7 infusions days) and 
time block (six 5 minute time blocks) as the within subjects factors (with the exception 
of hole category, which was analyzed with only infusion day as the within subjects 
factor). The dependent variables were several locomotor variables and two nose poke 
response variables. Separate statistical analyses were conducted for each variable. A 
one-way ANOVA was conducted on the baseline data to ensure that there were no 
individual differences prior to treatment days. For any variable in which the baseline 
ANOVA indicated significant group differences, a repeated measures ANCOVA was 
performed, using the baseline data as a co-variate. Where appropriate, post-hoc pair-
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Front wall of chamber
Figure 2.2. Schematic of the hole-board numbering system in the automated activity 
monitor, indicating four comer holes (1,4, 13, and 16), four centre holes (6, 7, 10, and
11), and eight wall holes (2, 3, 5, 8, 9, 12, 14, and 15).
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wise comparisons were conducted using Tukey's HSD or Sidak. Significance was set to 
a  = .05.
2.3 Results
2.3.1 Cannula Placement
For those animals that were perfused (low-dose PPA, n = 9; PBS, n = 3), 
histological analysis showed that cannula tips were correctly located within the right 
lateral ventricle in all animals (see Figure 2.3). Unfortunately, we were unable to verify 
cannula placement in those animals that were decapitated (high-dose PPA, n = 11; PBS 
n = 12).
2.3.2 Locomotor Variables
2.3.2.1 Baseline. A one-way ANOVA was performed on the baseline data for 
each locomotor variable. The one-way ANOVAs were not significant for total distance 
travelled, horizontal movement time, vertical movement time, or any of the repetitive 
activity measures (number of stereotypic movements, number of clockwise revolutions, 
and number of counterclockwise revolutions). Thus, there were no differences in 
locomotor activity among the treatment groups for these behavioural measures prior to 
the first infusion day. The one-way ANOVA was significant on baseline day for number 
of horizontal movements and number of vertical movements; therefore, baseline data 
were used as a covariate on infusion days for these variables.
2.3.2.2 Horizontal activity measures. Analysis revealed a significant day x 
treatment interaction for number of horizontal movements (ANCOVA), F( 12, 186) = 
3.25, p  < .01, and horizontal movement time (ANOVA), F(12, 192) = 2.74, p  < .05. 
There was a significant main effect of treatment for total distance traveled (ANOVA),
41
Figure 2.3. Representative photomicrograph showing proper cannula placement (arrow) 
into the right lateral ventricle using an H&E stain
F(2, 32) = 16.67,p <  .001. In general, PPA infusions produced an increase in all three 
horizontal activity measures that was dose dependent. High-dose PPA infused rats 
travelled further, made more horizontal movements, and spent more time traveling 
horizontally than PBS rats across infusion days. Low-dose PPA animals showed the 
same effects as high-dose PPA animals, but not until later into the infusion schedule.
Post-hoc analyses were conducted to determine differences between treatment 
groups across infusion days or across time. As seen in Figure 2.4A, high-dose PPA 
animals made significantly more horizontal movements than both PBS animals (on 
infusion days 2, and 4-7 (p < .05)), and low-dose PPA animals (on infusion day 2 (p < 
.05)) across infusion days. Low-dose PPA animals made significantly more horizontal 
movements than PBS animals on infusion days 6 and 7 (p < .05). There were no 
significant differences among treatment groups for number of horizontal movements on 
infusion days 1 and 3.
Across the 30 minute testing sessions, the ANCOVA showed a significant time x 
treatment interaction for number of horizontal movements, FT 10, 155) = 8.35,/? < .001. 
Post-hoc analyses were conducted across the six 5 minute time bins for number of 
horizontal movements. On infusion day 1, there were no significant differences among 
groups during the entire 30 minute testing session (see Figure 2.4B). On infusion day 4, 
low-dose PPA animals made significantly less horizontal movements than PBS animals 
during the first 5 minutes {p < .05), and high-dose PPA animals made significantly more 
horizontal movements than PBS animals between 20 and 25 minutes (p < .05; see Figure 
2.4C). There were no significant differences among treatment groups for all other times 




Figure 2.4. Mean number of horizontal movements + SEM  across infusion days (A) or 
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15), 
low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals. 
Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatment groups on that particular infusion day or that particular 
time (p < .05; no superscripts indicate no significant difference between groups).
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horizontal movements than PBS animals between 10 and 15 minutes and between 20 
and 30 minutes (p < .05; see Figure 2.4D). Low-dose PPA animals also made 
significantly more horizontal movements than PBS animals between 5 and 10 minutes 
(p  < .05). For the first 5 minutes, and between 15 and 20 minutes, there were no 
significant differences among treatment groups. In general (other than the first infusion 
day), both PPA groups showed a slight decrease in number of horizontal movements 
across time within testing sessions, whereas, PBS animals showed a steep decline in 
number of horizontal movements across time within testing sessions.
A similar pattern was seen across infusion days for horizontal movement time as 
for number of horizontal movements (see Figure 2.5). High-dose PPA animals spent 
significantly more time traveling horizontally than PBS animals on all but the first 
infusion day (infusion days 2-7, p  < .05). High-dose PPA animals also spent 
significantly more time traveling horizontally than low-dose PPA animals on infusion 
day 2 (p < .05). Low-dose PPA animals spent significantly more time traveling 
horizontally than PBS animals toward the end of the infusion schedule (infusion days 6 
and 7 , (p<  .05).
Post-hoc analyses for total distance traveled across infusion days were similar to 
number of horizontal movements and horizontal movement time. High-dose PPA 
animals traveled significantly more than PBS animals on infusion days 2-7 (p < .05; see 
Figure 2.6). High-dose PPA animals also traveled significantly more than low-dose PPA 
animals on infusion day 3 {p < .05). Low-dose PPA animals traveled significantly more 
than PBS animals on infusion days 4, 6, and 7 (p < .05). There were no significant 
differences among treatment groups for total distance traveled on infusion day 1.
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Figure 2.5. Mean horizontal movement time (s) + SEM  across infusion days in PBS (n = 
15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
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Figure 2.6. Mean total distance traveled (cm) + SE M across infusion days in PBS (n = 
15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
2.3.2.3 Vertical activity measures. The ANCOVA revealed a significant day x 
treatment interaction for number of vertical movements, F(12, 186) = 2.40,/? < .05, but 
no significant time x treatment interaction, F(10, 155) = .27, ns. Post-hoc analysis across 
infusion days showed that low-dose PPA animals made significantly more vertical 
movements than PBS animals on infusion days 4, 6, and 7 (/? < .05; see Figure 2.7). 
High-dose PPA animals also made significantly more vertical movements than PBS 
animals on infusion day 6. There were no significant differences among treatment 
groups on infusion days 1-3, and 5.
For vertical movement time, the ANOVA showed a significant time x treatment 
interaction, F(10, 160) = 6.49,/? < .001. There was no significant main effect of 
treatment, F(2, 32) = 1.58, ns, or day x treatment interaction, F(12, 192) = .82, ns. Post- 
hoc analysis across time and within a testing session revealed that on infusion day 1, 
high-dose PPA animals had significantly shorter vertical movement time than PBS 
animals during the first 5 minutes (/? < .05, data not shown). For the remaining 25 
minutes, there were no significant differences among treatment groups for vertical 
movement time. On infusion day 4, there were no significant differences among 
treatment groups for vertical movement time during the entire 30 minute testing session 
(data not shown). On infusion day 7, there were no significant differences among 
treatment groups for vertical movement time for the first 20 minutes of the testing 
session. During the remainder of the testing session, low-dose PPA animals had 
significantly longer vertical movement time than PBS (time 20-30,/? < .05) and high- 
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Figure 2.7. Mean number of vertical movements + SEM  across infusion days in PBS (n 
= 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
2.3.2.4 Repetitive activity measures. The ANOVA revealed a significant day x 
treatment interaction for number of stereotypic movements, F( 12, 192) = 3.15,/? < .01. 
Across days, the number of stereotypic movements depended on the treatment groups 
(see Figure 2.8A). In general, both PPA groups showed an increase in the number of 
stereotypic movements across infusion days; whereas, PBS animals remained relatively 
constant in the number of stereotypic movements across infusion days. Post-hoc 
analyses revealed that high-dose PPA animals made significantly more stereotypic 
movements than both PBS animals (on infusion days 3-7 (p<  .05)), and low-dose PPA 
animals (on infusion days 3 and 6 (p < .05)). In addition, low-dose PPA animals made 
significantly more stereotypic movements than PBS animals on infusion days 6 and 7 (p 
< .05). There were no significant differences among treatment groups for number of 
stereotypic movements on infusion days 1 and 2.
There was also a significant time x treatment interaction for number of 
stereotypic movements, F(10, 160) = 8.30,/? < .001. Across time, PBS animals showed 
a decrease in the number of stereotypic movements. Both PPA groups showed a 
decrease in the number of stereotypic movements across time, but much more gradually 
than PBS animals. Post-hoc analysis for infusion day 1 showed that low-dose PPA 
animals made significantly fewer stereotypic movements than both PBS and high-dose 
PPA animals between 15 and 20 minutes (p < .05; see Figure 2.8B). There were no 
significant differences among treatment groups for number of stereotypic movements 
during the remainder of the testing session. On infusion day 4, high-dose PPA animals 
made significantly more stereotypic movements than PBS animals during the first 5 





Figure 2.8. Mean number of stereotypic movements + SEM  across infusion days (A) or 
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15), 
low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals. 
Means accompanied by different superscripts (i.e., a, b, or c) indicate a significant 
difference between treatment groups on that particular infusion day or that particular 
time (p < .05; no superscripts indicate no significant difference between groups).
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no significant differences among treatment groups at any other times during the testing 
session. On infusion day 7, high-dose PPA animals made significantly more stereotypic 
movements than PBS animals during the entire 30 minute testing session (time 0-30,/? < 
.05; see Figure 2.8D). Low-dose PPA animals also made significantly more stereotypic 
movements than PBS animals in 3 time bins (time 0-5 and time 20-30,/? < .05).
The ANOVA revealed a significant main effect of treatment for clockwise 
revolutions, F(2, 32) = 12.87,/? < .001, and counterclockwise revolutions, F(2, 32) = 
12.15,/? < .001. There was no significant day x treatment interaction for either 
clockwise, F( 12, 192) = 1.87, ns, or counterclockwise revolutions, F(12, 192) = 1.97, ns. 
In general, PPA infusions produced an increase in revolutions that was dose dependant. 
High-dose PPA animals made more clockwise and counterclockwise revolutions than 
PBS animals across infusion days. Low-dose PPA animals showed similar effects, but 
not until later into the infusion schedule.
Post-hoc analyses revealed an identical pattern across infusion days for 
clockwise and counterclockwise revolutions. High-dose PPA animals made significantly 
more clockwise and counterclockwise revolutions than PBS animals on infusion days 3 
to 7 (/? < .05; see Figure 2.9 for clockwise revolutions). Low-dose PPA animals made 
significantly more clockwise and counterclockwise revolutions than PBS animals on 
infusion days 6 and 7 (/? < .05). There were no significant differences among treatment 
groups for clockwise or counterclockwise revolutions on infusion day 1 or 2.
Across the 30 minute testing session, the ANOVA showed a significant time x 
treatment interaction for clockwise revolutions, F(10, 160) = 2.87,/? < .05, but not for 
counterclockwise revolutions, F(10, 160) = 1.81, ns. In general, PBS animals showed a
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Figure 2.9. Mean number of clockwise revolutions + SEM  across infusion days in PBS 
(n = 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
53
sharp decline in number of clockwise revolutions across time within a testing session. In 
contrast, high-dose PPA animals showed a more gradual decline in clockwise 
revolutions within the first half of the testing session, and during the second half of the 
testing session, the number of clockwise revolutions remained relatively stable. Low- 
dose PPA animals showed a pattern more consistent with PBS animals across time 
within the first 3 infusion days, and then switched to a pattern similar to high-dose PPA 
across time for the remainder of the infusion schedule. On infusion day 1, post-hoc 
analyses showed that there were no significant differences among treatment groups for 
number of clockwise revolutions during the first 20 minutes of the testing session. For 
the remaining 10 minutes, high-dose PPA made significantly more clockwise 
revolutions than PBS animals (p < .05; data not shown). On infusion day 4, high-dose 
PPA animals made significantly more clockwise revolutions than PBS animals, but only 
between 15 and 20 minutes (p < .05; data not shown). During the last infusion day, high- 
dose PPA animals made significantly more clockwise revolutions than PBS animals for 
2 time bins (time 5-10 and time 15-20 ,p <  .05; data not shown). Low-dose PPA animals 
made significantly more clockwise revolutions than PBS animals during the first 5 
minutes (p < .05) and the last 15 minutes (p < .05).
2.3.3 Nose Poke Variables
2.3.3.1 Nose poke counts. The one-way ANOVA performed on the baseline data 
for total nose poke counts revealed no significant group differences. Therefore, there 
were no significant differences among treatment groups in number of nose pokes prior 
to the first infusion day.
The ANOVA revealed a significant day x treatment interaction across infusion 
days for number of nose pokes, F( 12, 192) = 2.96, p  < .01. As seen in Figure 2.10A,
PPA infusions resulted in a dose-dependent increase in number of nose pokes toward the 
end of the infusion schedule. Post-hoc analyses showed that high-dose PPA animals 
made significantly more nose pokes than PBS animals on infusion days 5 and 6 {p <
.05). On infusion day 7, low-dose PPA animals made significantly more nose pokes than 
PBS animals (p < .05). There were no significant differences among treatment groups 
for number of nose pokes on infusion days 1 through 4.
There was a significant time x treatment interaction for number of nose pokes, 
F(10, 160) = 5.11, p  < .01. Across time within a testing session, PBS animals showed a 
steep decrease in number of nose pokes. In contrast, high-dose PPA animals showed a 
slower decrease in number of nose pokes across time. Low-dose PPA animals resembled 
PBS animals across time for most of the infusion days, with the exception of infusion 
days 6 and 7, where low-dose PPA animals showed a pattern more similar to high-dose 
PPA animals across time. Post-hoc analysis on infusion day 1 showed that there were no 
significant differences among treatment groups for number of nose pokes during the first 
20 minutes of the testing session (see Figure 2.10B). During the last 10 minutes, high- 
dose PPA animals made significantly more nose pokes than PBS animals (p < .05). On 
infusion day 4, high-dose PPA animals made significantly more nose pokes than PBS 
animals during 2 time bins (time 10-15 and time 20-25, p  < .05; see Figure 2.10C). 






Figure 2.10. Mean number of nose pokes + SEM  across infusion days (A) or across time 
(B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 15), low-dose PPA 
(0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) infused animals. Means 
accompanied by different superscripts (i.e., a or b) indicate a significant difference 
between treatment groups on that particular infusion day or that particular time {p < .05; 
no superscripts indicate no significant difference between groups).
than PBS animals between 10 and 30 minutes (p < .05; see Figure 2.10D). Low-dose 
PPA animals made significantly more nose pokes than PBS animals during the last 10 
minutes of the testing session (p < .05).
2.3.3.2 Hole category. A one-way ANOVA was performed on the baseline data 
for each hole category variable (i.e., comer, wall, and centre nose pokes). The ANOVAs 
failed to reveal any significant group differences for any of the hole category variables.
The ANOVA revealed a significant main effect of treatment for number of 
comer nose pokes, F(2, 32) = 4.13 ,p <  .05, but not for number of wall nose pokes, F( 2, 
32) = 2.99, ns, or for number of centre nose pokes, F(2, 32) = 2.15, ns. In general, all 
treatment groups made a similar proportion of comer nose pokes, wall nose pokes, and 
centre nose pokes (see Figure 2.11 A, B, and C, respectively). Post-hoc analysis for 
number of corner nose pokes showed that PBS animals made significantly more comer 
nose pokes (in proportion to total nose pokes) than high-dose PPA animals on infusion 
days 4 and 6. On all other infusion days, there were no significant differences among 
treatment groups for number of comer nose pokes.
2.4 Discussion
To summarize, the results from the present study indicated that centrally infused 
PPA in adult male rats produced increased locomotor and nose poking behaviour in a 
dose-dependent manner. In general, high-dose PPA animals were more hyperactive, 
made more vertical movements, displayed more stereotypic and repetitive movements, 
and nose poked more often than PBS animals across infusion days and across time. 
Low-dose PPA animals showed similar effects to high-dose PPA animals, but not until 





Figure 2.11. Mean number of comer nose pokes (A), wall nose pokes (B), or centre 
nose pokes (C) expressed as a percent of total nose pokes + SEM  across infusion days 
in PBS (n = 15), low-dose PPA (0.052 M, n = 9), and high-dose PPA (0.26M, n = 11) 
infused animals. Means accompanied by different superscripts (i.e., a or b) indicate a 
significant difference between treatment groups on that particular infusion day {p < .05; 
no superscripts indicate no significant difference between groups).
activity levels similar to those of PBS animals at the start of the infusion schedule, but 
gradually increased to levels comparable to those of high-dose PPA animals by the end 
of the infusion schedule (i.e., infusion days 6 and 7). Additionally, analyses of hole 
category data indicated that all treatment groups made a similar proportion of wall and 
centre nose pokes. For comer nose pokes, PBS animals made proportionately more 
comer nose pokes than both PPA groups, but only on infusion days 4 and 6.
The increase in locomotor activity and stereotyped/repetitive behaviour 
following infusion of PPA in the current study is consistent with, but not identical to, 
previous work using the PPA rodent model (MacFabe et ah, 2007, 2008). Both the 
current and previous work used the same chronic infusion schedule over seven days 
(two infusions per day), as well as the same automated activity monitors to measure 
locomotor activity. The PPA dose used by MacFabe and colleagues was identical to that 
of the high-dose PPA group used in the current experiment. Despite the similarities in 
experimental design, the animals in the present investigation displayed much greater 
levels of horizontal activity than in previous work. This was true for both PBS control 
animals and high-dose PPA animals. This is particularly notable for total distance 
traveled. For instance, on infusion day 3, the mean total distance traveled was 2968 cm, 
4357 cm, and 8086 cm for PBS, low-dose PPA, and high-dose PPA animals, 
respectively. In contrast, previous work showed an approximate mean total distance 
traveled of 1000 cm in PBS animals and 3700 cm in PPA animals on infusion day 3 
(MacFabe et al., 2007). Unlike the horizontal movement measures, the vertical 
movement measures and number of stereotypic movements in PBS and high-dose PPA
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animals in the current study were similar to that of earlier work (MacFabe et al., 2008; 
Thomas et al., 2010)
Given that the present experiment used the same strain and gender of rat (i.e., 
male Long-Evans) and the same dose and infusion regimen of PPA (i.e., two infusions 
per day for seven consecutive days), and that PBS animals also showed an increase in 
horizontal activity measures, it is highly unlikely that the increase was due to a 
fundamental difference in the ability of these particular rats to metabolize or compensate 
for PPA infusions, as compared to rats used in previous work using this model. The 
most plausible explanation for the increase in horizontal activity seen in the current 
experiment is the addition of the hole-board on the floor of the automated activity 
monitors. The hole-board was the only difference in experimental design in the current 
study suggesting that exploration in the hole-board apparatus may influence overall 
locomotor activity.
Several studies have shown that locomotor activity varies independently of nose 
poking in rodents (Abel, 1995; Durcan & Lister, 1989; File & Wardill, 1975a, 1975b), 
but others have found no such dissociation or mixed results depending on drug treatment 
(Kliethermes & Crabbe, 2006; Moy et al., 2008). Kliethermes and Crabbe showed that 
although drug treatment resulted in similar effects on both locomotor and nose poking 
behaviours at a group level, analysis at the individual level in untreated mice revealed 
that these behaviours could vary independently. Overall, there appears to be a 
complicated and equivocal relationship between nose poking and locomotion as 
measured in the hole-board apparatus.
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Both PPA groups showed a decrease in locomotor behaviour within a 30 minute 
testing session. This decrease could reflect PPA metabolism and is consistent with the 
known 18 to 57 minute half-life of PPA when administered to rats (Brusque et al.,
1999). Across infusion days, low-dose PPA animals gradually reached levels of 
locomotor activity and nose poking comparable to that of high-dose PPA animals. 
Chronic low doses of PPA eventually led to abnormal motor behaviour, suggesting that 
compensatory mechanisms were unable to effectively counteract the effects of PPA. 
These compensatory mechanisms may include increased synthesis of certain enzymes, 
such as propionyl CoA decarboxylase which metabolizes PPA, or carbonic anhydrase 
which helps maintain acid-base balance (Nguyen et ah, 2007; Schlue, Domer, Rempe, & 
Riehl, 1991)
Propionic acid has several physiological/biochemical effects that alter neural 
function which can account for the increased locomotor behaviour seen in PPA-infused 
animals. PPA can inhibit Na+/ K+ ATPase, increase NMDA receptor sensitivity, 
promote intracellular calcium release, and elevate nitric oxide, all of which can alter 
neurotransmission in brain regions relevant to locomotor behaviour (de Mattos-Dutra et 
ah, 2000; Wajner et ah, 2004; Wyse et ah, 1998).
As a weak organic acid, PPA can passively accumulate in CNS cells resulting in 
a reduction in intracellular pH, which has many physiological consequences (Karuri, 
Dobrowsky, & Tannock, 1993). Previous work in our laboratory has shown that PPA 
and other short chain fatty acids (i.e., butyric acid and sodium acetate) produce similar 
behavioural impairments, but the non-acidic analogue of PPA, 1-propanol, did not 
produce behavioural impairments, suggesting that pH dependent mechanisms are an
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important component of the observed effects (MacFabe et al., 2007; Shultz et al., 2008, 
2009; Thomas et al., 2010). Intracellular acidification of neurons is known to increase 
the synthesis and release of several neurotransmitters that can influence locomotor 
activity, including glutamate, dopamine, norepinepherine, and serotonin (Cannizzaro, 
Monastero, Vacca, & Martire, 2003; Remblier et al., 1999; Severson, Wang, Pieribone, 
Dohle, & Richerson, 2003). Furthermore, 3-nitropropionic acid, a derivative of PPA, 
causes motor abnormalities and is used as a rodent model of Huntington’s disease, 
emphasizing that intracellular pH reduction is linked to increased locomotor behaviour 
(Brouillet, Jacquard, Bizat, & Blum, 2005).
Another consequence of intracellular acidification is a reduction in intercellular 
coupling via the rapid and reversible closure of gap junctions (Rorig et al., 1996). Gap 
junctions play a vital role in electrotonic transmission in brain areas involved in 
locomotor activity, including the basal ganglia, prefrontal cortex, and hippocampal 
formation (O’Donnell & Grace, 1997; Velazquez, Han, & Carlen, 1997). In addition, 
intrastriatal infusions of gap junction blockers produce movement stereotypies in 
rodents (Moore & Grace, 2002). Thus, the increased locomotor behaviour seen in PPA 
treated rats could be a consequence of the closure of gap junctions.
In addition to the abnormal locomotor behaviour observed in PPA treated 
animals, there was also an increase in nose poking compared to controls. PPA infusions 
led to a dose-dependent increase in nose poking toward the end of the infusion schedule. 
Nose poking, sometimes referred to as head-dipping, has typically been interpreted as 
representing exploratory behaviour or investigation of a novel environment (File & 
Wardill, 1975a, 1975b). However, many researchers have argued that nose poking in the
hole-board apparatus does not measure exploratory behaviour, but instead reflects the 
anxiety state of the animal (Takeda, Tsuji, & Matsumiya, 1998), an escape response 
(Brown & Nemes, 2008), or stereotyped behaviour (Makanjuola, Hill, Maben, Dow, & 
Ashcroft, 1977). The widespread opinions regarding what the hole-board task is actually 
measuring in rodents are likely due, at least in part, to methodological differences. 
Across studies, the hole-board apparatus often differs in total number of holes (usually 4 
or 16), the location of the holes (centrally, peripherally, or equally dispersed within the 
floor of the apparatus), the diameter of the holes (allowing the rodent to either insert 
only its nose, or its entire head), the depth of the hole (ranging from 1 cm to 20 cm), and 
whether the hole-board is enclosed or open (occasionally the hole-board is used as an 
elevated platform without walls). In addition, the amount of time that rodents are 
observed within the hole-board apparatus ranges widely (e.g., 5 minutes, 10 minutes, 30 
minutes, and 3 hours). The variability of the hole-board apparatus has led to conflicting 
interpretations of nose poking behaviour, and this underscores the need for a 
standardized hole-board apparatus. To my knowledge, no study has acknowledged these 
methodological differences, and in order for the hole-board test to be valid and useful, it 
is imperative that these issues be addressed in the future.
Another important consideration in the interpretation of the hole-board task is 
the complexity of exploratory behaviour. When rodents are exposed to a novel 
environment, they often exhibit exploratory behaviour, such as locomoting around the 
environment or orienting toward novelty (Ballaz, 2009; Berlyne, 1950). Presumably, 
exploratory behaviour allows the animal to gather relevant survival-related information 
about the unfamiliar place, such as food sources, mating opportunities, or the presence
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of predators. With continued exposure, the environment becomes familiar, and 
exploration decreases as animals become habituated. Decreased exploratory behaviour 
in response to repeated exposure to a novel environment is one of the most common 
forms of habituation seen in rodents, and habituation is often considered the simplest 
form of learning (Leussis & Bolivar, 2006). However, there are a variety of factors 
influencing exploratory behaviour, including arousal level, attention, learning, memory, 
and fear of novelty (Berlyne, 1969; Bronson, 1968). The presence of these mitigating 
factors in exploratory behaviour makes the interpretation of any measure of exploration 
complex. Although levels of nose poking may reflect exploratory behaviour, any 
increase or decrease in nose poking following treatment may be due to a variety of 
factors, suggesting that interpretation of results may require complementary information 
from evaluations of anxiety, learning and memory, etc.
Given the complexity of interpreting nose poking behaviour in the hole-board 
apparatus, there are several possible explanations for the dose-dependent increase in 
nose pokes following PPA infusion. Assuming that nose poking represents exploratory 
behaviour, one possible explanation is that PPA infusions resulted in an increase in 
exploratory behaviour secondary to cognitive deficits in learning and memory. 
Intersession habituation, measured as a decrease in exploratory behaviour upon re­
exposure to a novel environment, is considered to be an indicator of learning and 
memory (Leussis & Bolivar, 2006). Since PPA infusions resulted in an increase in 
exploratory behaviour across testing sessions, this may indicate that PPA animals failed 
to retain information about the novel environment. However, it is important to mention
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that control animals maintained a relatively stable level of nose poking across infusion 
days, which would signify little or no habituation to the hole-board apparatus.
Another possible explanation for the results in the current study is that nose 
poking may encompass both exploratory and repetitive behaviour. Makanjuola and 
colleagues (1977) described exploratory behaviour as the overall pattern of nose pokes, 
whereas repeated responses into one hole was considered a sign of stereotypy. The hole 
category data from the current study allows for the assessment of the pattern of nose 
pokes within the apparatus, and therefore exploratory behaviour. Overall, animals made 
a similar proportion of comer, wall, and centre nose pokes. This suggests that PPA 
infusions did not alter exploratory behaviour. Although the current study did not 
measure repeated responses into one hole, the increase in nose poking seen in PPA 
animals could plausibly result from repetitive patterns of nose poking. Studies using a 
hole-board with 16 empty holes (similar to the current study), have shown that there is a 
gradual transition from exploratory to stereotyped nose poking observed across time, 
with most exploratory nose poking occurring within the first 10 minutes in the hole- 
board apparatus (Makanjuola et al., 1977; Makanjuola, Hill, Dow, Campbell, & 
Ashcroft, 1977). This trend was seen in both control and drug-treated animals, with 
control animals displaying some stereotyped nose poking (as defined by repeated 
responses to one hole).
Results from the current study are consistent with this interpretation. PBS 
animals displayed a relatively stable level of nose poking across infusion days. Across 
time, PBS animals showed a marked decrease in nose poking after the first 10 minutes 
within the hole-board apparatus. This suggests that in control animals, nose poking
represented mostly an exploratory response, as opposed to a repetitive response in the 
hole-board. In contrast, PPA infused animals showed an increase in nose poking 
behaviour across infusion days, which corresponded with a relatively consistent level of 
nose poking after the first 10 minutes within the apparatus, suggestive of a repetitive 
response.
There are a number of ways in which PPA might affect brain function to cause 
the behavioural impairments reported here. Histological examination of brain tissue in 
rodents has shown that PPA can induce an innate neuroinflammatory response, 
characterized by reactive astrogliosis and activated microglia in the hippocampus and 
neocortical white matter (MacFabe et al., 2007). Neuroinflammation is also known to 
occur in other diseases, such as Parkinson’s and Alzheimer’s disease, suggesting that 
this response may impair normal cognitive processes (Ferretti & Cuello, 2011; Whitton, 
2007). Activated microglia secrete cytokines and toxic substances (e.g., nitric oxide) 
that are potentially damaging to neurons, which may impair brain function (Barron, 
1995). However, fast-acting mechanisms caused by PPA, such as closure of gap 
junctions and pH-dependent increases in serotonin, may also explain the behavioural 
changes seen in the current study. Connexin-36 knock-out mice show deficits in normal 
spatial coding and short-term spatial memory, suggesting that electrical coupling of 
intemeurons in the hippocampus via gap junctions are important for spatial coding and 
cognition (Allen, Fuchs, Jaschonek, Bannerman, & Monyer, 2011). Moreover, studies 
have shown that 5-HT(l A) receptor agonists produce learning and memory deficits in 
rodents (Ogren et ah, 2008). It is possible that a fast-acting mechanism combined with 
neuroinflammation led to the behavioural impairments seen here.
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The synthesis and release of dopamine and serotonin following intracellular 
acidification by PPA may explain the stereotyped nose poking behaviour seen in these 
animals. Increases in both serotonin and dopamine in corticostriatal circuits of the brain 
have been linked to stereotyped and repetitive behaviour in rodents (Langen, Kas, Staal, 
van Engeland, & Durston, 2011) and humans (Langen, Durston, Kas, van Engeland, & 
Staal, 2011). Indeed, studies using the hole-board apparatus suggest that some aspects of 
the dopaminergic system are involved in nose poking behaviour (Kliethermes & Crabbe, 
2006).
The findings from the current study indicate that PPA induces locomotor 
behaviour and stereotyped/repetitive behaviour similar to the symptoms seen is ASD. 
Individuals with ASD often display hyperactivity, motor stereotypies, and repetitive 
behaviour (Matson, Dempsey, & Fodstad, 2009; Murray, 2010). Additionally, those 
with ASD typically display decreased exploratory behaviour compared to normal 
individuals when exposed to novel environments (Pierce & Courchesne, 2001). This is 
contradictory to results seen in PPA-infused rodents, assuming that increased nose 
poking should be considered increased exploratory behaviour, but this interpretation of 
the hole-board task is still under considerable debate.
Importantly, the proposed mechanisms underlying the behavioural impairments 
seen is PPA-infused animals are also theoretically linked to ASD. Aberrations in 
dopamine and serotonin have been reported in autistic individuals (Chugani, 2004; 
Previc, 2007), and treatment of repetitive behaviours has been shown to be effective 
with serotonin reuptake inhibitors, and serotonin and dopamine antagonists (McDougle,
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Kresch, & Posey, 2000; McPheeters et al., 2011). An active neuroinflammatory process 
has also been observed in those with ASD (Morgan et al., 2010; Vargas et al., 2005).
In conclusion, central infusions of PPA in adult male rats resulted in locomotor 
abnormalities and increased repetitive behaviour compared to controls. The direct or 
indirect physiological properties of PPA, such as intracellular acidosis and 
neuroinflammatory changes, may be a plausible mechanism underlying these 
behavioural effects. The current findings are consistent with the symptoms seen in 
individuals with ASD, and taken together with previous findings using this model, 
support the use of PPA in an animal model of autism. Further research at critical 
developmental periods is needed to better understand the mechanisms responsible for 
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Chapter 3
Intracerebroventricular propionic acid induces perseverative behaviour in rats 




The prevalence of autism spectrum disorders (ASD), a class of 
neurodevelopmental disorders, has increased dramatically over the last several decades, 
and currently affects approximately 1 in 110 children (Boyle et al., 2011). ASD is 
characterized by three major behavioural symptom domains: communication deficits, 
abnormal social interaction, and repetitive/restricted behaviours (American Psychiatry 
Association, 1994). Other associated symptoms may include hyperactivity, sensitivity to 
sensory stimuli, cognitive deficits, seizures, and gastrointestinal (GI) disturbances 
(Kootz, Marinelli, & Cohen, 1982; Markram, Rinaldi, & Markram, 2007; Murray, 2010; 
Tuchman, Moshe, & Rapin, 2009; Williams et al., 2011). ASD has traditionally been 
viewed as a strongly genetic based disorder, however increasing evidence suggests that 
environmental, dietary, and gastrointestinal factors may also be contributing factors 
(Ratajczak, 2011; Williams et al., 2011).
Propionic acid (PPA) is a short-chain fatty acid (SCFA) endogenously produced 
as an intermediary of fatty acid metabolism and as a metabolite of bacterial fermentation 
in the gut (Al-Lahham, Peppelenbosch, Roelofsen, Vonk, & Venema, 2010; Thompson 
et al., 1990). In the GI tract, PPA is capable of altering gut motility, dilating colonic 
arteries, and activating mast cells (Karaki et al., 2006; Mitsui, Ono, Karaki, &
Kuwahara, 2005). PPA is able to cross the gut-blood barrier and enter the systemic 
circulation, where it can gain access to the central nervous system (CNS) by crossing the 
blood-brain barrier by passive or active means (Bergersen, Rafiki, & Ottersen, 2002). 
Once in the CNS, PPA has widespread effects including changes in neurotransmitter 
synthesis and release, lipid metabolism, mitochondrial function, immune activation, and
gene expression (Brass & Beyerinck, 1988; Parab, Nankova, & La Gamma, 2007; 
MacFabe et al., 2008; Wyse et al., 1998). Furthermore, intracellular acidification, due to 
PPA accumulation within cells, can alter neurotransmitter release, inhibit gap junctions, 
and promote intracellular calcium release (Remblier, Pontcharraud, Tallineau, Piriou, & 
Huguet, 1999; Rorig, Klausa, & Sutor, 1996). All of the CNS effects of PPA have the 
potential to affect neuronal communication and therefore behaviour.
PPA may be associated with the etiology and pathogenesis of ASD. Anecdotal 
evidence from parents suggests a worsening of behavioural symptoms following 
consumption of refined wheat and dairy products (Jyonouchi, 2009). A recent 
randomized controlled trial of casein- and gluten-free diets in children with ASD 
supports these anecdotal reports, with an improvement in some behavioural symptoms 
following implementation of this diet (Whiteley et al., 2010). Interestingly, PPA is 
present in dairy as a result of the manufacturing process and is used as a preservative in 
refined wheat products, though PPA produced by enteric bacteria may also increase 
following consumption of these products (Brock & Buckel, 2004; Cummings, Pomare, 
Branch, Naylor, & Macfarlane, 1987). A subset of children with ASD, particularly those 
with associated GI symptoms or behavioural regression, have increased levels of the 
enteric bacterial species Clostridium and Desulfovibrio, both of which are known to 
produce PPA and other SCFAs (Finegold et al., 2002; Finegold, 2011; Parracho, 
Bingham, Gibson, & McCartney, 2005). Valproic acid can elevate levels of SCFAs, 
including PPA, and exposure to valproic acid early in development increases the risk of 
ASD (Omoy, 2009). Although there are currently no studies directly measuring PPA in 
ASD patients, there is indirect evidence linking PPA to autism, including metabolic
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impairment of fatty acids and deficiencies in carnitine and glutathione, consistent with 
PPA’s physiological effects (Bell et al., 2004; Filipek, Juranek, Nguyen, Cummings, & 
Gargus, 2004; James et al., 2009).
The physiological effects of PPA and the evidence linking PPA to autism led our 
laboratory to propose that alterations in PPA may be related to some of the symptoms 
seen in ASD, and therefore we recently investigated the effects of PPA treatment in 
rodents as a potential animal model of ASD. We found that intracerebroventricular 
(ICV) infusions of PPA in adult rats resulted in hyperactivity, repetitive behaviours, 
kindled seizures, social impairments, cognitive deficits, altered brain phospholipid 
profiles, widespread oxidative stress, and an innate neuroinflammatory response 
(MacFabe et al., 2007, 2008; Nie et al., 2011; Shultz et al., 2009, 2008; Thomas et al., 
2010). The behavioural, biochemical, electrophysiological, and neuropathological 
effects following PPA treatment is consistent with human findings in ASD (Bauman & 
Kemper, 2005; Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005; Wiest, 
German, Harvey, Watkins, & Hertz-Picciotto, 2009). In order to assess the effects of 
PPA during development, our most recent work investigated the central and systemic 
effects of PPA in adolescent and neonatal rodents, and thus far our results have been 
consistent with symptoms seen in autistic patients and lend further credence to the PPA 
rodent model of ASD (for review of these results see Foley, Tichenoff, Ossenkopp, & 
MacFabe, 2010; MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shams, Kavaliers, 
Foley, Ossenkopp, & MacFabe, 2009).
The goal of the current study was to further validate this animal model and 
extend the findings reported by Meeking and colleagues (2009), which assessed the
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effect of central administration of two doses of PPA on locomotor and repetitive 
behaviour in the hole-board task. In that study, PPA treatment resulted in a dose- 
dependent increase in locomotor behaviour and nose poking behaviour (a measure of 
repetitive behaviour from the hole-board apparatus), analogous to the symptoms of ASD 
(Meeking, Foley, Tichenoff, Ossenkopp, & MacFabe, 2009). The current study also 
assessed the effects of two doses of PPA using the hole-board apparatus, but unlike the 
previous study, relevant olfactory stimuli (i.e. clean and soiled bedding, see Method) 
was placed within the wells of the hole-board apparatus as a means of measuring 
perseverative behaviour. It was expected that PPA treatment would result in 




Thirty-two naive male Long-Evans rats were used, weighing 200-225 g 
(approximately 47-49 days old) at the time of arrival to the facility. Animals were 
housed individually in standard rat polypropylene cages (W 26 x L 48 x H 21 cm) with 
ad libitum access to food (LabDiet RMH 3000) and tap water in a temperature- 
controlled colony room (21 ± °C) on a 12:12 h light-dark cycle (lights on at 07:00 h). 
Behavioural testing occurred during the light phase of the cycle. Animals were left 
undisturbed for one week prior to the cannulation surgery. All procedures followed the 
guidelines of the Canadian Council on Animal Care and were approved by the 
University of Western Ontario Animal Use Subcommittee.
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3.2.2 Apparatus
Locomotor activity was monitored using three Versamax Animal Activity 
Monitors (AccuScan Model DCM-8, Columbus, OH, USA). Each monitor consisted of 
a clear Plexiglas open field chamber (W 40 cm x L 40 cm x H 30.5 cm) and a clear 
plastic lid with air holes. Movement was recorded via a grid of infrared beams located 
on all four sides of the chamber for horizontal activity (16 equally spaced beams 2.54 
cm apart and 4.5 cm from the floor) and a grid of infrared beams located on two sides of 
the chamber for vertical activity (16 beams located 15 cm above the box floor). The 
automated activity monitors were equipped with a hole-board on the floor of the 
chamber to measure nose poke responses (see Figure 3.1A-D). The hole-board is 
an elevated platform with 16 equally spaced holes (2.54 cm diameter) with small wells 
(5.08 cm diameter) underneath each hole. A wire mesh screen was placed over each well 
(see Figure 3. ID). A set of infrared beam sensors, separate from those recording 
locomotor activity, are located between the well and the platform, allowing for nose 
poke counts for each hole to be recorded via beam breaks. VersaMax Analyzer software 
(Accuscan Model VSA-16, Columbus, OH) recorded data from each automated activity 
monitor and relayed it to a computer that stored the data for subsequent analysis. All 
sessions within the automated activity monitors were video-recorded and later reviewed 
to ensure accuracy of the computer generated nose poke data.
3.2.3 Procedure
3.2.3.1 Surgery. To induce anaesthesia, animals were placed into a sealed plastic 
box into which 4% isoflurane at 2 L/min oxygen was introduced. The animal was then 
placed into a Kopf stereotaxic device equipped with a gas flow mask delivering 2.5%
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Figure 3.1. Photographs of the automated activity monitors equipped with a hole-board 
on the floor of the chamber. (A) Front view; (B) Top-down view; (C) Top-down view 
with platform removed to show the 16 equally spaced wells beneath the floor of the 
chamber; (D) Close-up of wells with wire mesh screens.
isoflurane at 500 mL/min of oxygen to maintain anaesthesia during surgery. Under 
aseptic conditions, right lateral ventricular cannulation surgery was performed (AP -1.4 
mm, ML -1.8 mm, DV -3.0 mm). Each animal was implanted with a 23-gauge guide 
cannula with the tip in the right lateral ventricle in accordance with a standard rat atlas 
(Paxinos & Watson, 1998). The indwelling cannula was secured chronically using 
dental acrylic anchored in place with small stainless steel screws inserted into the skull. 
A removable obturator sealed the guide cannula and was only removed for infusions 
during the experiment. Animals received a subcutaneous injection of analgesic 
(ketoprofen, 1 mL/kg) immediately post-operatively. After surgery, animals were kept 
warm under a heating lamp until righting responses and locomotion returned. Animals 
were housed individually and allowed two weeks recovery prior to testing.
3.2.3.2 Treatment groups and infusion procedure. Following recovery, animals 
were randomly assigned to one of three groups: high-dose PPA (0.26 M, 4.0 pL, n =
11), low-dose PPA (0.052 M, 4.0 pL, n = 10), or phosphate buffered saline vehicle 
(PBS, 4.0 pL, n = 11). Propionic acid was dissolved in PBS vehicle, and all solutions 
were buffered to pH 7.5 using concentrated HCL or NaOH. Each animal received 
intracerebroventricular (ICV) infusions twice daily (separated by 4 hours) for seven 
consecutive days. The first infusion occurred during the light phase at 09:00 h. Solutions 
were infused using a 30 gauge injection cannula that was connected to a Sage syringe 
pump with sterile PE10 tubing. The tip of the injection cannula protruded 0.5 mm 
beyond the tip of the guide cannula. The syringe pump dispensed 4.0 pL of solution 
over a 60 s interval, and the injection cannula remained in place for an additional 60 s 
before being removed.
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3.2.3.3 Testing. Following two weeks of recovery, rats were handled and 
habituated to the automated activity monitors for two days (30 minutes per day). On the 
third day, baseline levels of activity and nose poke responses were recorded in the 
absence of infusion. During the seven treatment days, animals were placed in the 
automated monitors following the second infusion of the day for 30 minutes to record 
locomotor activity and nose poke counts (six 5 minute time bins). All wells within the 
hole-board platform remained empty with wire mesh screens for habituation, baseline, 
and the first two treatments days. On treatment days 3 through 6, clean bedding was 
placed in one centre well and soiled bedding was placed in another centre well (holes 6 
and 11, counter-balanced within treatment groups, see Figure 2). All animals were 
exposed to soiled bedding from one unfamiliar male rat (i.e., bedding from an 
individually housed rat in a separate colony room soiled for 72 hours) on each of 
treatment days 3 to 6. The soiled bedding was from a different unfamiliar male rat for 
each particular treatment day (i.e., soiled bedding was used from 4 different unfamiliar 
male rats, one for each of days 3 through 6). On the seventh treatment day, the soiled 
bedding was from the experimental rat’s own cage (also soiled for 72 hours). Rats were 
weighed daily to monitor health.
3.2.3.4 Perfusions. The day after behavioural testing was completed, rats were 
euthanized via intraperitoneal injection (euthanyl 270 g/mL, ~0.5 mL per animal). 
Animals were transcardially perfused with a PBS/4% paraformaldehyde solution. The 





Locomotor activity was analyzed using eight distinct measures. The horizontal 
activity measures analyzed were: total distance -  total horizontal distance (cm) 
travelled; horizontal movement time -  amount of time (s) an animal was engaged in 
horizontal movement; and number of horizontal movements -  the number of horizontal 
movements separated by a 1 s stop time. The vertical activity measures analyzed were: 
vertical movement time -  amount of time (s) an animal spent in a vertical position; and 
number of vertical movements -  number of vertical movements separated by a 1 s stop 
time. The repetitive locomotor measures were: clockwise revolutions -  the numbers of 
times an animal moved around in a clockwise circle of at least 2 inches in diameter; 
counterclockwise revolutions -  the number of times an animal moved around in a 
counterclockwise circle of at least 2 inches in diameter; and the number of stereotypic 
movements -  repeated breaking of the same infrared beam separated by 1 sec or more.
Nose poke behaviour was analyzed using total nose poke counts, hole category, 
and difference scores. Total nose poke counts are the total number of nose pokes across 
an entire testing session (includes all 16 different holes in the hole-board). Hole category 
data classified the holes into four categories based on location within the open-field 
apparatus in order to determine if there was a pattern of hole preference. The four hole 
categories based on location included comer holes (1,4, 13, and 16); centre holes (6, 7, 
10, and 11), and wall holes (2, 3, 5, 8 9, 12, 14, and 15) (see Figure 3.2). In order to 
determine preferences between the soiled and clean bedding across treatment days, 
difference scores were calculated. The total number of nose pokes at the hole with soiled 
bedding (SB) was calculated as a percent of total nose pokes for that particular testing
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Back wall of chamber
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9 10 11 12
13 14 15 16
Front wall of chamber
Figure 3.2. Schematic of the hole-board numbering system in the automated activity 
monitor, indicating four comer holes (1,4, 13, and 16), four centre holes (6, 7, 10, and 
11), and eight wall holes (2, 3, 5, 8, 9, 12, 14, and 15).
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session for each individual animal to control for differences in total nose pokes between 
animals. The same was done for the hole with clean bedding (CB) and a nearby empty 
hole (EH). The SB percent minus the CB percent is the difference score (SB-CB) that 
determined the preference for soiled bedding (i.e., a positive score would indicated a 
preference for soiled bedding) or the preference for clean bedding (i.e., a negative score 
would indicate a preference for clean bedding). The SB percent minus the EH percent is 
the difference score (SB-EH) that determined the preference for soiled bedding (i.e., a 
positive score would indicated a preference for soiled bedding) or the preference for an 
empty hole (i.e., a negative score would indicate a preference for an empty hole). The 
CB percent minus the EH percent is the difference score (CB-EH) that determined the 
preference for clean bedding (i.e., a positive score would indicated a preference for 
clean bedding) or the preference for an empty hole (i.e., a negative score would indicate 
a preference for an empty hole).
3.2.5 Statistical Analysis
Data were analyzed for main effects and interactions using a repeated measures 
split-plot analysis of variance (ANOVA) with drug treatment (PBS, low-dose PPA, and 
high-dose-PPA) as the between-subjects factor and infusion day (7 infusions days) and 
time block (six 5 minute time blocks) as the within subjects factors (with the exception 
of nose poke counts, hole category, and difference scores, which were analyzed with 
only infusion day as the within subjects factor). Hole category and difference score data 
were analyzed using separate ANOVAs for each set of infusion days (i.e., days 1 to 2, 
days 3 to 6, and day 7). The dependent variables were several locomotor and nose poke 
variables. Separate statistical analyses were conducted for each variable. A one-way
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ANOVA was conducted on the baseline data to ensure that there were no individual 
differences prior to treatment days. For any variable in which the baseline ANOVA 
indicated significant group differences, a repeated measures ANCOVA was performed, 
using the baseline data as a co-variate. Where appropriate, post-hoc comparisons were 
conducted using Tukey's HSD or Sidak. Significance was set to a  = .05.
3.3 Results
3.3.1 Cannula Placement
Histological analysis showed that cannula tips were correctly located within the 
right lateral ventricle in all animals (see Figure 3.3).
3.3.2 Locomotor Variables
3.3.2.1 Baseline. A one-way ANOVA was performed on the baseline data for 
each locomotor variable. The one-way ANOVAs were not significant for total distance 
travelled, horizontal movement time, the vertical activity measures (number of vertical 
movements and vertical movement time), or any of the repetitive activity measures 
(number of stereotypic movements, number of clockwise revolutions, and number of 
counterclockwise revolutions). Thus, there were no differences in locomotor activity 
among the treatment groups for these behavioural measures prior to the first infusion 
day. The one-way ANOVA was significant on baseline day for number of horizontal 
movements; therefore, baseline data were used as a covariate on infusion days for this 
variable.
3.3.2.2 Horizontal activity measures. The ANCOVA revealed a significant day x 
treatment interaction for number of horizontal movements, F( 12, 168) = 6.48,/? < .001. 
ANOVAs showed a significant main effect of treatment for horizontal movement time,
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Figure 3.3. Representative photomicrograph showing proper cannula placement (arrow) 
into the right lateral ventricle using an H&E stain
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F(2, 29) = 21.64,p <  .001, and for total distance traveled, F(2, 29) = 19.78,p <  .001. In 
general PPA infusions resulted in a dose dependent increase in horizontal activity 
measures. Across infusion days, high-dose PPA animals made more horizontal 
movements, spent more time travelling horizontally, and traveled further than PBS 
animals. Low-dose PPA animals showed a moderate increase in these same measures 
across infusion days, reaching somewhat similar levels as high-dose PPA animals by the 
end of the infusion schedule.
Post-hoc analyses were conducted to determine differences among treatment 
groups across infusion days for number of horizontal movements. As seen in Figure 3.4, 
high-dose PPA animals made significantly more horizontal movements than both PBS 
and low-dose PPA animals on infusion days 3 through 7 (p < .05). In addition, low-dose 
PPA animals made significantly more horizontal movements than PBS animals on 
infusion day 6 (p < .05). There were no significant differences among treatment groups 
for number of horizontal movements on infusions days 1 and 2.
Across the 30 minute testing sessions, there was a significant time x treatment 
interaction for number of horizontal movements, F(10, 140) = 14.15,/? < .001. Post-hoc 
analyses were conducted across the six 5 minute time bins for each infusion day. On 
infusion day 1, there were no significant differences among groups for number of 
horizontal movements for the entire 30 minute testing session (data not shown). On 
infusion day 4, high-dose PPA animals made significantly more horizontal movements 
than both PBS animals during 3 time bins (time 10-15 and time 20-30, p  < .05) and also 
low-dose PPA animals during 2 time bins (time 20-30, p  < .05; data not shown). There 

















0.052 M PPA 






; / / / 
/ / / 
/  /  / / 
















































Figure 3.4. Mean number of horizontal movements + SEM  across infusion days in PBS 
(n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a, b, or c) indicate a 
significant difference between treatments on that particular infusion day (p < .05; no 
superscripts indicate no significant difference between groups).
93
movements during the remainder of the testing session. On infusion day 7, high-dose 
PPA animals made significantly more horizontal movements than PBS animals during 
the last 25 minutes of the testing session (time 5-30,/? < .05; data not shown). High-dose 
PPA animals also made significantly more horizontal movements than low-dose PPA 
animals between 15 and 20 minutes (p < .05) and between 25 and 30 minutes (p < .05). 
Furthermore, low-dose PPA animals made significantly more horizontal movements 
than PBS animals between 10 and 15 minutes (p < .05). In general, (other than the first 
infusion day), high-dose PPA animals showed a very minor decrease in number of 
horizontal movements across time within testing sessions; whereas, PBS animals 
showed a sharp decrease. In contrast, low-dose PPA animals showed a moderate 
decrease in number of horizontal movements across time within testing sessions.
A similar pattern was also observed across infusion days for horizontal 
movement time as for number of horizontal movements. High-dose PPA animals spent 
significantly more time moving horizontally than both PBS (infusion days 3-7,/? < .05) 
and low-dose PPA animals (infusion days 4-6,/? < .05; see Figure 3.5A). Low-dose PPA 
animals also spent significantly more time moving horizontally than PBS animals on 
infusion day 7 (/? < .05). There were no significant differences among treatment groups 
for horizontal movement time for the first two infusion days.
Across the 30 minute testing sessions, there was a significant time x treatment 
interaction for horizontal movement time, F(10, 145) = 3.58,/? < .01. Post-hoc analyses 
conducted across the six 5 minute time bins revealed that on infusion day 1, there were 
no significant differences among treatment groups for horizontal movement time across 




Figure 3.5. Mean horizontal movement time (s) + SEM  across infusion days (A) or 
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 11), 
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals. 
Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatment groups on that particular infusion day or that particular 
time (p < .05; no superscripts indicate no significant difference between groups).
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spent significantly more time moving horizontally than PBS animals during the entire 30 
minute testing session (time 0-30,/? < .05; see Figure 3.5C). In addition, high-dose PPA 
animals spent significantly more time moving horizontally than low-dose PPA animals 
for the last 20 minutes of the testing session (time \0-30,p  < .05). On infusion day 7, 
high-dose PPA animals spent significantly more time moving horizontally than PBS 
animals during the entire testing session, with the exception of the first 5 minutes (time 
5-30,p  < .05; see Figure 3.5D). High-dose PPA animals also spent significantly more 
time moving horizontally than low-dose PPA animals during the last 5 minutes of the 
testing session (time 25-30,p <  .05). In addition, low-dose PPA animals spent 
significantly more time moving horizontally than PBS animals between 10 and 15 
minutes (p < .05). Across time, all treatment groups showed a decrease in horizontal 
movement time; however, the rate of decline depended on the treatment group. In 
general, (other than the first infusion day), high-dose PPA animals showed a gradual 
decrease, low-dose PPA animals showed a moderate decrease, and PBS animals showed 
a sharp decrease in horizontal movement time across time and within a testing session. 
All treatment groups had the most pronounced decrease in horizontal movement time 
within the first 15 minutes of a testing session, while remaining relatively stable for the 
last 15 minutes of a testing session.
Post-hoc analyses across infusion days for total distance travelled were similar to 
number of horizontal movements and horizontal movement time. On infusion days 3 
through 7, high-dose PPA animals traveled significantly further than PBS animals (p < 
.05; see Figure 3.6). Furthermore, high-dose PPA animals traveled significantly further 
than low-dose PPA animals on infusion days 4 and 6 (p < .05). Low-dose PPA animals
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Figure 3.6. Mean total distance traveled (cm) + SE M across infusion days in PBS (n =
11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
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traveled significantly further than PBS animals on the last infusion day (p < .05). There 
were no significant differences among treatment groups for total distance traveled on 
infusion days 1 and 2.
3.3.2.3 Vertical activity measures. Due to a technical error with the locomotor 
activity boxes, 5 PBS animals and 5 high-dose PPA animals were excluded from 
statistical analyses for both vertical activity measures (i.e., high-dose PPA, 0.26 M, n = 
5; low-dose PPA, 0.052 M, n = 10; PBS, n = 5). Analyses revealed no significant main 
effects or interactions for number of vertical movements, or vertical movement time, 
with the exception of a significant main effect of treatment for number of vertical 
movements, F(2, 17) = 11.83,/? < .01. Post-hoc analyses across infusion days for 
number of vertical movements revealed that high-dose PPA animals made significantly 
more vertical movements than both PBS animals (infusion days 6 and l , p  < .05), and 
also low-dose PPA animals (infusion day 6, p  < .05) toward the end of the infusion 
schedule (data not shown).
3.3.2.4 Repetitive activity measures. Analyses showed a significant main effect 
of treatment for number of stereotypic movements, F{2, 29) = 19.26, p  < .001. As seen 
in Figure 3.7A, PPA infusions resulted in an increase in stereotypic movements for 
high-dose animals, but not for low-dose animals. Post-hoc analyses across infusion days 
showed that high-dose PPA animals made significantly more stereotypic movements 
than PBS animals on infusion days 3 through 7 {p < .05). High-dose PPA animals also 
made significantly more stereotypic movements than low-dose PPA animals on infusion 
days 4 to 7 (p < .05). There were no significant differences among treatment groups for 




Figure 3.7. Mean number of stereotypic movements + SEM  across infusion days (A) or 
across time (B. infusion day 1; C. infusion day 4; D. infusion day 7) in PBS (n = 11), 
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals. 
Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatment groups on that particular infusion day or that particular 
time {p < .05; no superscripts indicate no significant difference between groups).
There was also a significant time x treatment interaction for number of 
stereotypic movements, F( 10, 145) = 9.84,/? < .001. Across time, high-dose PPA, low- 
dose PPA, and PBS animals showed a minor, moderate, and sharp decrease in number 
of stereotypic movements, respectively. Post-hoc analyses across time within a testing 
session showed that on infusion day 1, high-dose PPA animals made significantly more 
stereotypic movements than both PBS and low-dose PPA animals between 5 and 10 
minutes (/? < .05; see Figure 3.7B). Between 20 and 25 minutes, high-dose PPA animals 
made significantly more stereotypic movements than low-dose PPA animals (/? < .05). 
On infusion day 4, high-dose PPA animals made significantly more stereotypic 
movements than PBS animals during 4 time bins (time 10-30,/? < .05; see Figure 3.7C). 
Additionally, high-dose PPA animals made significantly more stereotypic movements 
than low-dose PPA animals during 2 time bins (time 20-30,/? < .05). On infusion day 7, 
high-dose PPA animals made significantly more stereotypic movements than PBS 
animals during the last 20 minutes of the testing session (time 10-30,/? < .05; see Figure 
3.7D). High-dose PPA animals also made significantly more stereotypic movements 
than low-dose PPA animals during the last 5 minutes of the testing session (time 25-30; 
/ ?<• 05).
Analyses revealed a significant main effect of treatment for clockwise, F(2, 29)
= 12.51,/? < .001, and counterclockwise revolutions, F(2, 29) = 14.00,/? < .001. There 
were no significant day x treatment or time x treatment interactions for clockwise and 
counterclockwise revolutions. In general, high-dose PPA animals made more 
revolutions than PBS animals. In contrast, low-dose PPA animals were similar to PBS 
animals for number of revolutions. Post-hoc analyses conducted across infusion days
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showed that high-dose PPA animals made significantly more clockwise revolutions than 
PBS animals (infusion days 3 to 7, p  < .05; see Figure 3.8) and low-dose PPA animals 
(infusion days 1, and 4 to 7, p  < .05). A somewhat similar pattern was seen across 
infusion days for counterclockwise revolutions (data not shown). High-dose PPA 
animals made significantly more counterclockwise revolutions than PBS (infusion days 
3, 4, 6, and 7,p <  .05) and low-dose PPA animals (infusion days 4 and 6 ,p  < .05).
3.3.3 Nose Poke Variables
3.3.3.1 Nose poke counts. The one-way ANOVA performed on the baseline data 
for total nose poke counts failed to show any significant effects. Therefore, there were 
no significant differences among treatment groups in number of nose pokes prior to the 
first infusion day.
Analysis revealed a significant main effect of treatment for number of nose 
pokes, F(2, 29) = 4.49, p  < .05. As seen in Figure 3.9, PPA infusions resulted in an 
increase in number of nose pokes, but post-hoc analyses across infusion days showed no 
significant differences among treatment groups on any infusion day except day 6 where 
low-dose PPA animals made significantly more nose pokes than PBS animals (p < .05).
3.3.3.2 Hole category. A one-way ANOVA was performed on the baseline data 
for each hole category variable (i.e., comer, wall, and centre nose pokes). The ANOVA 
was not significant for number of comer or wall nose pokes, but was significant for 
number of centre nose pokes. Therefore, baseline data was used as a covariate for 
analysis for centre nose pokes.
The ANOVAs for comer nose pokes and wall nose pokes on infusion days 1 and 
2 and infusion days 3 through 6 showed no significant main effect of day or main effect
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Figure 3.8. Mean number of clockwise revolutions + SEM  across infusion days in PBS 
(n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
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Figure 3.9. Mean number of nose pokes + SEM  across infusion days in PBS (n = 11), 
low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26 M, n = 11) infused animals. 
Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatments on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups).
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of treatment and no significant day x treatment interaction. On infusion day 7, the one­
way ANOVAs for comer nose pokes and wall nose pokes showed no significant 
treatment effects. The ANCOVA for centre nose pokes on infusion days 1 and 2 
revealed a day x treatment interaction, F(2, 28) = 3.50,p <  .05. However, post-hoc 
analyses across infusion days showed no significant differences among treatment groups 
for number of centre nose pokes for infusion days 1 and 2. The ANCOVA for centre 
nose pokes on infusion days 3 through 6 showed no significant main effect of day or 
main effect of treatment and no significant day x treatment interaction. On infusion day 
7, the ANCOVA for centre nose pokes showed no significant treatment effects.
In summary, all treatment groups made a similar proportion of comer nose 
pokes, wall nose pokes, and centre nose pokes (see Figure 3.10A, B, and C, 
respectively) across infusion days. However, the proportion of nose pokes changed 
substantially from infusion days 1 and 2, to infusion days 3 through 7. For comer and 
wall nose pokes, the proportions decreased from infusion day 2 to 3; whereas, for centre 
nose pokes the proportions increased.
3.3.3.3 Hole preference. The repeated measures ANOVAs for the SB-CB 
difference score (i.e., soiled bedding percent minus clean bedding percent; see Method 
section for details) on infusion days 1 and 2 and infusion days 3 through 6 showed no 
significant main effect of day or main effect of treatment and no significant day x 
treatment interaction. On infusion day 7, the one-way ANOVA for the SB-CB 
difference score showed that the effect of treatment was significant, F(2, 29) = 5.56, p  < 




Figure 3.10. Mean number of comer nose pokes (A), wall nose pokes (B), or centre 
nose pokes (C) expressed as a percent of total nose pokes + SEM  across infusion days 
in PBS (n = 11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) 
infused animals. Means accompanied by different superscripts (i.e., a or b) indicate a 
significant difference between treatment groups on that particular infusion day (p < .05; 
no superscripts indicate no significant difference between groups.
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had significantly higher SB-CB difference scores than PBS animals (p < .05; see Figure 
3.11).
The repeated measures ANOVAs for the SB-EH difference score (i.e., soiled 
bedding percent minus empty hole percent; see Method for details) on infusion days 1 
and 2 and infusion days 3 through 6 showed no significant main effect of day or main 
effect of treatment and no significant day x treatment interaction (data not shown). On 
infusion day 7, the one-way ANOVA for the SB-EH difference score showed no 
significant treatment effects (data not shown).
The repeated measures ANOVA for the CB-EH difference score (i.e., clean 
bedding percent minus empty hole percent; see Method for details) on infusion days 1 
and 2 showed a main effect of day, F( 1, 29) = 6.18, p  < .05. Neither the main effect of 
treatment, F(2, 29) = .79, ns, nor the day x treatment interaction, F(2, 29) = .59, ns, were 
significant. Post-hoc analyses showed no significant differences among treatment groups 
for CB-EH preference on infusion days 1 and 2 (see Figure 3.12). The repeated 
measures ANOVA for the CB-EH difference score on infusion days 3 through 6 showed 
a day x treatment interaction, F{6, 87) = 3.05, p  < .01. Post-hoc analyses revealed that 
low-dose PPA animals had significantly greater CB-EH difference scores than high-dose 
PPA animals on infusion day 5 (p < .05; see Figure 3.12). On infusion day 7, the one­
way ANOVA for the CB-EH difference score showed a significant effect of treatment, 
F(2, 29) = 4.84, p  < .05. Post-hoc analysis showed that PBS animals had significantly 
higher CB-EH difference scores than both PPA groups on infusion day 7 (p < .05; see 
Figure 3.12).
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Figure 3.11. Mean difference score (SB-CB) + SEM  across infusion days in PBS (n =
11), low-dose PPA (0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused 
animals. Means accompanied by different superscripts (i.e., a or b) indicate a significant 
difference between treatment groups on that particular infusion day {p < .05; no 
superscripts indicate no significant difference between groups). The total number of 
nose pokes at the hole with soiled bedding (SB) was calculated as a percent of total nose 
pokes for that particular infusion day for each individual animal. The same was done for 
the hole with clean bedding (CB). The SB percent minus the CB percent is the 
difference score (SB-CB) that determines the preference for soiled bedding (i.e., a 
positive score indicates a preference for soiled bedding) or the preference for clean 
bedding (i.e., a negative score indicates a preference for clean bedding).
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Figure 3.12. Mean difference score (CB-EH) + SEM  in PBS (n = 11), low-dose PPA 
(0.052 M, n = 10), and high-dose PPA (0.26M, n = 11) infused animals. Means 
accompanied by different superscripts (i.e., a or b) indicate a significant difference 
between treatment groups on that particular infusion day (p < .05; no superscripts 
indicate no significant difference between groups). The total number of nose pokes at 
the hole with clean bedding (CB) was calculated as a percent of total nose pokes for that 
particular infusion day for each individual animal. The same was done for the empty 
hole (EH). The CB percent minus the EH percent is the difference score (CB-EH) that 
determines the preference for clean bedding (i.e., a positive score indicates a preference 
for clean bedding) or the preference for an empty hole (i.e., a negative score indicates a
preference for an empty hole).
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3.4 Discussion
The present results indicate that PPA treatment increased locomotor and 
repetitive activity and induced perseverative behaviours in adult rats. Abnormalities in 
locomotor activity were most apparent in the high-dose PPA group, which showed 
hyperactivity and repetitive movements compared to control animals across infusion 
days and across time. Low-dose PPA animals had an overall trend of increased 
locomotor activity compared to control animals, with the most prominent effects 
observed toward the end of the infusion schedule. However, these increases were 
moderate, and not as pronounced as high-dose PPA animals. Treatment with either dose 
of PPA resulted in a general increase in nose poking behaviour. Additionally, PPA- 
infused animals failed to modify their behavioural patterns in the hole-board test on 
infusion day 7, as observed by a persistent preference for the hole containing soiled 
bedding.
Hyperactivity following PPA treatment in the current study, as measured by 
horizontal activity measures, is consistent with previous work in our laboratory using 
the same infusion schedule and dose of PPA (0.26M twice daily for seven days) 
(MacFabe et al., 2007, 2008). However, both PBS and high-dose PPA animals showed 
considerably greater levels of horizontal locomotion across infusion days than rodents 
from respective treatment groups in previous experiments. In contrast, vertical and 
repetitive movement measures in control and high-dose PPA animals were similar to 
that of earlier work (MacFabe et ah, 2008; Thomas et ah, 2010). The addition of the 
hole-board to the automated activity monitors may explain the reason for the overall 
increase in horizontal movement seen across treatment groups, especially given relevant
olfactory stimuli was present in the wells for most of the infusion schedule.
Accordingly, it may be worthwhile to assess locomotor behaviour without the hole- 
board in low-dose PPA animals in future experiments using this model, as the 0.052 M 
PPA dose was used for the first time in the current study.
Locomotor behaviour in PPA treated animals decreased over a 30 minute testing 
session, which is congruent with the known half-life of PPA when administered to rats 
(Brusque et ah, 1999), although the decrease in locomotor behaviour across time could 
be a result of habituation to the automated activity monitors. Low-dose PPA animals had 
gradual, albeit moderate, increases in locomotor activity across infusion days, 
suggesting that chronic low doses of PPA may have led to a decline in physiological 
mechanisms that metabolize or clear PPA. Such physiologic compensatory mechanisms 
may include synthesis of metabolizing or pH balancing enzymes, such as propionyl CoA 
decarboxylase or carbonic anhydrase, respectively (Nguyen et al., 2007; Schlue, Domer, 
Rempe, & Riehl, 1991).
In addition to a dose-dependent increase in locomotor activity, PPA treatment 
also led to a general increase in nose poking behaviour (e.g., a main effect of treatment 
on nose poking behaviour), that, unlike locomotor activity, was not dose-dependent. 
However, post-hoc analyses showed that with the exception of infusion day 6 (where 
low-dose PPA animals made significantly more nose pokes than PBS animals), PPA 
animals did not nose poke significantly more than PBS animals on any particular 
infusion day. The interpretation of the general increase in nose poking following PPA 
treatment is somewhat complex. Nose poking is usually described as a measure of 
exploratory behaviour, which is influenced by several mitigating factors including level
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of arousal, learning and memory, and attention (Berlyne, 1969; Bronson, 1968; File & 
Wardill, 1975). Others have proposed that nose poking represents an anxiety/escape 
response or stereotyped behaviour (Makanjuola, Hill, Maben, Dow, & Ashcroft, 1977; 
Takeda, Tsuji, & Matsumiya, 1998). Another possibility, suggested by Makanjuola and 
colleagues (1977), is that the overall pattern of nose poking within the hole-board 
represents exploratory behaviour, whereas repeated nose poking at one particular hole 
represents repetitive/stereotyped behaviour. Thus, the hole category analysis used in the 
current study, which assessed the pattern of nose poking within the apparatus, may be a 
better indicator of overall exploratory activity. All treatment groups showed similar 
patterns of hole-board exploration, as indicated by the proportion of comer, wall, and 
centre nose pokes, suggesting that PPA treatment did not alter exploratory behaviour. 
Although not measured here, the overall increase in nose poking seen in PPA animals 
could plausibly result from repetitive patterns of nose poking, but hyperactivity cannot 
be entirely ruled out.
PPA treatment also resulted in a persistent pattern of responding as indicated by 
hole preference data (i.e, SB-CB and CB-EH difference scores). All treatment groups 
preferred investigating the hole with soiled bedding over the hole with clean bedding 
from infusion day 3 through 6. In addition, animals in all treatment groups showed 
greater interest in the hole with clean bedding over an empty hole on infusion day 3, but 
this interest declined to infusion day 6 (with the exception of the low dose PPA group on 
infusion day 5). The most interesting finding is seen on infusion day 7, when the 
animal’s own soiled bedding was used. On infusion day 7, PBS animals reversed their 
hole preference, showing a preference for the hole with clean bedding over the hole with
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soiled bedding, whereas both PPA groups show a preserved interest in the hole with 
soiled bedding. This is also apparent in the CB-EH difference score for infusion day 7, 
where PBS animals showed a renewed interest in the hole with clean bedding 
(comparable to that on infusion day 3 when the bedding was first introduced into the 
apparatus). In contrast, on infusion day 7 both PPA groups somewhat maintained their 
levels of interest in the clean bedding hole over the empty hole comparable to infusion 
day 6.
Although it is clear that PPA treatment resulted in a persistent behavioural 
response on infusion day 7, it is not entirely clear whether this perseveration reflects a 
social deficit (and/or an olfactory deficit) or a true cognitive deficit (e.g., in learning and 
memory). Rodents rely on olfaction to obtain information about their environment, and 
this is particularly important for social behaviour (Miranda, Ortiz-Godina, & Garcia, 
2009). The soiled bedding used in this experiment has inherent olfactory information 
that is socially relevant. As a result, the persistent pattern of responding in PPA-infused 
animals could represent a deficit in social information processing. Alternatively, the 
perseveration may be due to an olfactory deficit in which PPA treated animals cannot 
distinguish between their own odour and that of a novel conspecific.
The perseverative effect of PPA treatment is also consistent with a cognitive 
deficit interpretation. The results of the current study are similar to the cognitive 
impairments in learning and memory observed in previous work using the PPA rodent 
model (MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2009). PPA- 
treated adult or adolescent rats were not impaired during the acquisition phase of the 
water maze or T-maze, respectively, but were impaired during the reversal phase.
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Similarly, PPA-treated animals in the present study were comparable to control animals 
during the initial exposure to soiled and clean bedding within the hole-board apparatus, 
but failed to change their behavioural response on infusion day 7 when the environment 
required a different directional response. The lack of impairment during initial exposure 
to the hole-board apparatus suggests that the cognitive mechanisms required for 
processing information within the task were not impaired by PPA.
Importantly, the perseverative behaviours seen in PPA treated animals do not 
appear to be related to other factors, such as baseline hole preference differences, an 
inability to distinguish between soiled and clean bedding, or a lack of exploration of the 
hole-board apparatus. There was no significant difference between treatment groups for 
hole preference (i.e., SB-CB, SB-EH, and CB-EH difference scores) on infusion days 1 
and 2, when all wells were empty, suggesting that there were no baseline differences in 
hole preference. All treatment groups showed an increase in nose poking on infusion 
day 3, when clean and soiled bedding was initially placed in the apparatus. Placement of 
bedding in the centre holes led to a change in the pattern of hole-board exploration for 
all treatment groups. Specifically, the proportion of centre nose pokes increased 
dramatically. Additionally, all treatment groups had similar hole preferences from 
infusion day 3 to 6. Taken together, this suggests that PPA animals were capable of 
distinguishing between soiled and clean bedding. However, this does not completely 
rule out that PPA treatment led to more subtle olfactory deficits that made it difficult for 
animals to differentiate between their own and an unfamiliar male rat’s soiled bedding. 
All treatment groups made a similar proportion of comer, wall, and centre nose pokes 
across infusion days, suggesting that both PPA groups had hole-board exploration
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similar to the PBS animals. Altogether, these results indicate that the perseveration seen 
in PPA treated animals is not likely confounded by these factors.
PPA has many physiological consequences that alter brain function which can 
account for the behavioural abnormalities observed in this study. PPA inhibits Na+/ K+ 
ATPase, increases NMDA receptor sensitivity, promotes intracellular calcium release, 
and elevates nitric oxide, all of which can alter normal neuronal function and 
transmission (de Mattos-Dutra et ah, 2000; Nishiguchi, Hayashi, Shigetomi, Ueda, & 
Tomita, 1997; Wajner, Latini, Wyse, & Dutra-Filho, 2004; Wyse et al., 1998). 
Intracellular acidification subsequent to PPA accumulation has widespread effects on 
neurotransmitter release involving dopamine, glutamate, norepinepherine, and serotonin 
(Cannizzaro, Monastero, Vacca, & Martire, 2003; Remblier et al., 1999; Severson, 
Wang, Pieribone, Dohle, & Richerson, 2003), each of which can influence locomotor 
activity. Repetitive and stereotyped activity has been shown to result from increased 
levels of dopamine and serotonin in corticostriatal brain circuits, and pH-dependent 
release of these neurotransmitters may explain the increased nose poking behaviour seen 
in PPA animals (Langen, Durston, Kas, van Engeland, & Staal, 2011; Langen, Kas, 
Staal, van Engeland, & Durston, 2011). Increased serotonin may also help explain the 
perseverative effects of PPA, as serotonin receptor agonists have been shown to impair 
learning and memory (Ogren et al., 2008) and reduce social behaviour in rodents 
(Gonzalez, Andrews, & File, 1996).
Another pH-dependent effect of PPA is the rapid and reversible closure of gap 
junctions, which results in decreased intercellular coupling (Rorig, Klausa, & Sutor, 
1996). Gap junctions are necessary for synchronous electrical activity within the brain,
and animal and human studies have shown that gap junctions are important in the 
regulation o f locomotor activity and memory (Juszczak & Swiergiel, 2009). Indeed, 
studies using connexin 36 knockout mice and gap junction blockers in rodents have 
shown impairments in spatial memory and cognition and increased stereotypy, 
repectively (Allen, Fuchs, Jaschonek, Bannerman, & Monyer, 2011; Moore & Grace, 
2002). Thus, the increased locomotor behaviour, repetitive nose poking, and 
perseveration observed in PPA animals could be a result of the closure of gap junctions.
There are several plausible mechanisms for the perseverative effects of PPA 
treatment. PPA has been shown to result in increased astrogliosis and microglia 
activation in the hippocampus and white matter suggestive of an innate 
neuroinflammatory process in the absence of apoptotic neuronal loss (MacFabe et al., 
2007). Evidence from neuropathological conditions such as Parkinson’s and 
Alzheimer’s disease, which have similar inflammatory responses, suggests that 
neuroinflammation may play a role in impaired cognitive function (Ferretti & Cuello, 
2011; Whitton, 2007). Impaired brain function may also result from increased cytokines, 
secreted by activated microglia, which is potentially damaging to neurons (Barron, 
1995). Consequently, PPA may be inducing a neuroinflammatory response that impairs 
the function of brain structures important for learning and memory, such as the 
hippocampus, which may explain the perseveration seen in PPA animals (Leussis & 
Bolivar, 2006).
In addition, PPA is known to disrupt fatty acid metabolism in the mitochondria 
via the production of the cytotoxin propionyl Coenzyme A and by inhibiting carnitine 
function (Brass & Beyerinck, 1988). As a consequence of inhibiting carnitine function,
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PPA and other fatty acids can accumulate intracellularly with resultant increases in 
oxidative stress. Such a diffuse encephalopathic process could lead to cognitive 
impairments, not unlike those found in the organic acidemias (Wajner et al., 2004). In 
support of this hypothesis, previous work in our laboratory has shown that PPA 
treatment results in oxidative stress in widespread brain regions and alters brain lipid 
and acylcamitine profiles (MacFabe et al., 2008; Thomas et al., 2010).
PPA and related short chain fatty acids are also capable of inducing extensive 
alterations in CNS gene expression, presumably through inhibition of histone 
deacetylase or via modulation of second-messenger transduction systems (Parab et al., 
2007). Of particular interest to the current study, short chain fatty acids can induce 
phosphorylation of cyclic AMP response-element-binding protein (CREB), as 
demonstrated in both in vitro systems and in rodents using the PPA model (MacFabe et 
al., 2007; Shah, Nankova, Parab, & La Gamma, 2006). The transcription factor CREB is 
expressed ubiquitously in brain cells and is known to play a vital role in the epigenetic 
expression of genes involved in learning and memory (Carlezon, Duman, & Nestler, 
2005). Although not measured here, alterations in CREB-dependent memory pathways 
following PPA treatment may underlie the perseverative behavioural effects seen in the 
current study.
Results from the present experiment indicate that PPA treatment induced 
locomotor, repetitive, and perseverative behaviours reminiscent of the symptoms seen in 
ASD. Those with ASD frequently display hyperactivity and repetitive patterns of 
behaviour (Matson, Dempsey, & Fodstad, 2009; Murray, 2010), analogous to increased 
locomotor activity and repetitive nose poking seen in PPA treated rodents. Furthermore,
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individuals with ASD often display cognitive dysfunction, such as resistance to change 
or insistence on sameness and perseverative behaviours (Frith & Happe, 2005; Maes, 
Eling, Wezenberg, Vissers, & Kan, 2011). The pattern of persistent nose poking despite 
environmental change within the hole-board apparatus observed in animals treated with 
PPA is consistent with the cognitive deficits seen in human ASD.
Notably, the proposed underlying mechanisms of PPA-induced behavioural 
impairments are theoretically linked to ASD. Abnormalities in several neurotransmitters 
systems have been observed in autistic individuals, including dopamine and serotonin 
(Chugani, 2004; Previc, 2007). Moreover, serotonin reuptake inhibitors and serotonin 
and dopamine antagonists are reported to be effective in reducing repetitive thoughts 
and behaviours in children with ASD (McDougle, Kresch, & Posey, 2000; McPheeters, 
et al., 2011). An innate neuroinflammatory response, oxidative stress, mitochondrial 
dysfunction, and disordered fatty acid metabolism have also been found in autism 
(Chauhan, Chauhan, Brown, & Cohen, 2004; Morgan et al., 2010; Rossignol & 
Bradstreet, 2008; Vargas et al., 2005) (Wiest et al., 2009).
In summary, ICV infusions of PPA increased locomotor activity and repetitive 
behaviour, and induced perseveration in adult male rats. The ability of PPA to induce 
widespread changes in the CNS through intracellular acidification or metabolic 
dysfunction may offer a potential explanation for the behavioural deficits. Along with 
previous findings, the current study supports the use of PPA as a model of ASD as 
behavioural and neuropathological effects following PPA treatment resemble the 
symptoms and possible underlying pathology of ASD. An increase in short chain fatty 
acids, via alterations in enteric bacteria or impaired fatty acid metabolism, may be a
117
plausible environmental factor that triggers or exacerbates ASD in genetically 
susceptible sub-populations. Further research is needed to clarify which of the diverse 
physiological effects of PPA and other short chain fatty acids are responsible for ASD- 
like behaviour in rodents.
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The aims of the current studies were to (1) assess repetitive and perseverative 
behaviours in the hole-board apparatus following PPA treatment and (2) investigate the 
effects on behaviour of a low-dose of PPA (0.052 M) in comparison to that of a 
previously used dose of PPA (0.26 M). Both objectives were devised with the intention 
of further developing the PPA rodent model of ASD. In Chapter 2, locomotor and nose 
poking behaviour were examined in the hole-board apparatus following PPA treatment. 
Since this was the first time that the hole-board task was used within the PPA model, all 
wells within the apparatus remained empty across infusion days. Results showed that 
central infusions of PPA increased locomotor activity and repetitive nose poking 
behaviour in a dose-dependent manner. The experiment in Chapter 3 was designed to 
determine if placement of olfactory stimuli in the centre holes would change the pattern 
of hole-board exploration, whether animals demonstrated a selective preference for 
soiled or clean bedding, and most importantly whether animals would adapt their 
behaviour in response to a change in the environment (i.e., shift their hole preference on 
infusion day 7). When bedding was located in the centre holes, both PPA groups and the 
PBS group showed an increase in the proportion of centre nose pokes with a 
concomitant decrease in the proportion of comer and wall nose pokes suggestive of a 
change in the pattern of hole-board exploration in response to olfactory stimuli. All 
treatment groups showed a preference for soiled bedding from an unfamiliar male rat 
over clean bedding from infusion day 3 through 6. The most interesting finding occurred 
on infusion day 7, when PPA animals (regardless of dose) showed a preserved interest 
in the hole containing soiled bedding.
129
Results from Chapters 2 and 3 showed a dose-dependent increase in locomotor 
activity following PPA treatment. PPA-infused animals also showed an increase in nose 
poking behaviour. In contrast, the perseverative effects of PPA occurred regardless of 
the dose used. Previous work in our lab has also shown that the behavioural response to 
PPA in rodents is differentially influenced by the timing and spacing of PPA infusions 
using the same dose (e.g., 1 infusion a week for 5 weeks versus 2 infusions a day for 7 
days) (Foley et al., 2008). Investigation of the dose and timing effects of PPA allows for 
delineation of different behavioural phenotypes that occur as a result of variable PPA 
exposure. The fact that the rodent model of PPA allows for many behavioural and 
neuropathological phenotypes is useful given that autism disorders are highly 
heterogenous and occur across a spectrum of symptom severity (Ratajczak, 2011). 
Additionally, studying the behavioural response to different PPA regimens might be 
analogous to the variable exposure to environmental insults seen in human cases of 
autism. Exposure to infectious agents and environmental toxins during critical 
developmental periods may trigger ASD in genetically susceptible individuals (Fatemi, 
2008). The timing and dose of exposure to these environmental agents may influence the 
onset, severity, and lifelong modulation of autism (Herbert, 2010).
It is unlikely that an animal model will fully replicate the complexity of a human 
disease. However, animal models provide a means to explore the neurological, 
biochemical, and pathological mechanisms underlying disorders such as autism that 
would be impossible to do in humans. Understanding the common underlying 
mechanism(s) of a complex neurodevelopmental disorder through an animal model is 
imperative to the development of better diagnosis, prevention, and treatment. Indeed,
animal models led to effective pharmacological drug therapies used in depression 
(Willner & Mitchell, 2002). Similar benefits may be derived from the PPA rodent model 
of autism.
For the PPA rodent model of autism to be useful, effective, and relevant to ASD, 
it is important to optimize three types of validity within the model: face validity, 
construct validity, and predictive validity (Crawley, 2007; van der Staay, 2006). Face 
validity refers to the extent that the symptoms seen in the animal model are similar to 
those of the human disorder. Some autism symptoms, such as language deficits, may be 
uniquely human and therefore difficult or impossible to model in rodents. However, 
other fundamental symptoms of autism, such as social deficits and repetitive behaviour, 
can be more easily replicated using analogous behaviour in rats. For instance, the 
current study used total distance traveled as an analog to hyperactivity in autistic human 
patients. Central infusions of PPA in the current study produced hyperactivity, repetitive 
nose poking, and perseveration consistent with the symptoms observed in patients with 
autism (Frith & Happe, 2005; Maes, Eling, Wezenberg, Vissers, & Kan, 2011; Matson, 
Dempsey, & Fodstad, 2009; Murray, 2010). In addition, previous work has 
demonstrated social impairment, cognitive deficits, and restricted interests in PPA- 
treated rats congruent with those seen in ASD (MacFabe, Cain, Boon, Ossenkopp, & 
Cain, 2011; Shultz et al., 2008, 2009). Taken together, the behavioural effects seen in 
PPA-treated animals is similar to autism in humans, providing evidence for the face 
validity of the PPA model of autism. It would be interesting to assess whether PPA- 
treated animals show impairments in social communication as a means of modelling the 
language deficits seen in ASD. Crawley (2007) proposed that tests measuring
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vocalizations during social interactions or ultrasonic vocalizations by separated pups 
may be useful behavioural tests to evaluate communication deficits in rodents. Future 
studies of the PPA rodent model using communication -related tests would address 
another core symptom of ASD, further validating the model.
In addition to face validity, an optimal animal model should have construct 
validity and predictive validity (van der Staay, 2006). Construct validity refers to the 
extent that the animal model has a sound theoretical rationale based on the similarity of 
the animal model to the underlying causes of the disease. Predictive validity refers to the 
extent that the animal model shows an expected response to treatments used in the 
human disorder. For instance, if a clinical drug is effective in the treatment of autism, 
then the same drug should show a similar response within the animal model.
The evaluation of the construct validity of the PPA rodent model of autism is 
limited because of a lack of an existing comprehensive theory of the aetiology of autism. 
However, the similarities in the neuropathological, biochemical, and proposed 
mechanistic effects of PPA treatment and human ASD could represent a similar 
underlying aetiological process. For instance, PPA promotes intracellular calcium 
release, elevates nitric oxide, and increases the synthesis and release of dopamine and 
serotonin, all of which may help explain the increase in locomotor activity and repetitive 
behaviour observed in the current study (Nishiguchi, Hayashi, Shigetomi, Ueda, & 
Tomita, 1997; Wajner, Latini, Wyse, & Dutra-Filho, 2004). Similarly, individuals with 
ASD have been shown to have calcium signalling abnormalities, elevated plasma levels 
of nitric oxide, and aberrations in dopamine and serotonin neurotransmitter systems 
(Chugani, 2004; Gargus, 2009; Previc, 2007; Sweeten, Posey, Shankar, & McDougle,
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2004). Examination of brain tissue in rodents following PPA administration also bears 
resemblance to findings in human ASD cases. PPA treatment results in 
neuroinflammation, impaired glutathione metabolism, and altered fatty acid profiles 
reminiscent of the activated microglia, increased oxidative stress, and disordered 
mitochondrial fatty acid metabolism observed in human ASD (James et al., 2009; 
MacFabe et al., 2007; Rossignol & Bradstreet, 2008; Sajdel-Sulkowska, Lipinski, 
Windom, Audhya, & McGinnis, 2008; Thomas et al., 2010; Vargas, Nascimbene, 
Krishnan, Zimmerman, & Pardo, 2005). Furthermore, PPA has both 
electrophysiological and gastrointestinal effects which can account for the high co­
morbidity of seizures and intestinal disorders in ASD (MacFabe et al., 2007; Mitsui, 
Ono, Karaki, & Kuwahara, 2005; Tuchman, Moshe, & Rapin, 2009; White, 2003).
One of the most common and consistent neuropathological findings in the brain 
of those with ASD is reduced number and size of Purkinje cells in the cerebellum 
(Bauman & Kemper, 2005; Fatemi, et al., 2002; Palmen, van Engeland, Hof, & Schmitz, 
2004). Cerebellar dysfunction has been linked to reduced exploration and stereotyped 
behaviour in MRI studies of children with autism (Pierce & Courchesne, 2001), and 
repetitive behaviour and increased activity has been observed in a mouse model of 
Purkinje cell loss (Martin, Goldowitz, & Mittleman, 2010). Furthermore, prenatal 
exposure to valproic acid in rodents, a derivative of PPA, reproduces the cerebellar 
abnormalities associated with ASD (Ingram, Peckham, Tisdale, & Rodier, 2000). Given 
the ability of PPA to induce repetitive and stereotyped behaviour in the current study, it 
would be interesting to investigate whether Purkinje cell atrophy occurs in the
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cerebellum of PPA treated rodents. This would support further the construct validity of 
the PPA model.
Preliminary evidence exists for the predictive validity of the PPA model. 
Dopamine antagonists have been shown to be effective in reducing some of the 
behavioural symptoms in autism (McPheeters et al., 2011). Similarly, work in our lab 
has shown a decrease in PPA-induced locomotor behaviour as a result of treatment with 
dopamine receptor antagonists (Martins et al., 2008), providing initial support for the 
predictive validity of the model. Assessment of the effects of carnitine supplementation 
would be a reasonable next step in addressing the predictive validity of the PPA rodent 
model. Carnitine is essential for the proper metabolism of fatty acids within the 
mitochondria (Jones, McDonald, & Borum, 2010), and a relative carnitine deficiency 
has been observed in blood plasma of autistic patients (Filipek, Juranek, Nguyen, 
Cummings, & Gargus, 2004). A randomized double-blind clinical trial of L-camitine to 
treat ASD resulted in significant improvements in several clinical measurements of 
autism severity (Geier et al., 2011). Since studies in our lab have shown that PPA 
treatment in rodents results in altered plasma acylcamitine profiles similar to those in 
ASD (Thomas et al., 2010), future experiments using carnitine treatment in PPA-treated 
rats would be useful in assessing the predictive validity of the PPA model.
PPA and related short chain fatty acids may be a possible common underlying 
mechanism behind the multi-factorial aspects of ASD. Because PPA has the ability to 
cross both the gut-blood and blood-brain barriers, it is a plausible environmental link 
between brain, gastrointestinal, and dietary factors seen in ASD (Karuri, Dobrowsky, & 
Tannock, 1993). Rather than PPA being a direct cause of autism per se, elevated levels
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of PPA early in development may be an environmental risk factor which can trigger or 
exacerbate ASD or ASD related behaviours in genetically susceptible populations. It is 
important to note that there are no studies directly measuring PPA and related 
metabolites in ASD patients. However, there is some indirect evidence suggestive of 
increased PPA in autism, such as impaired fatty acid metabolism (Clark-Taylor & 
Clark-Taylor, 2004) , relative carnitine deficiency (Filipek et al., 2004), and reductions 
in essential polyunsaturated fatty acids levels (Vancassel et al., 2001). Moreover, 
increases in clostridial bacteria species, which produce PPA, have been observed in the 
gut of autistic patients (Finegold et al., 2002; Parracho, Bingham, Gibson, &
McCartney, 2005).
In conclusion, the present studies provide further support for the PPA rodent 
model of autism. Animals infused with PPA showed hyperactivity, increased repetitive 
behaviour, and perseveration consistent with the symptoms seen in human ASD. It is 
unclear which of the diverse effects of short-chain fatty acids are responsible for the 
ASD-like behaviour in rodents, and future studies are needed to address this question. 
Nevertheless, administration of PPA in rodents does show promise as an animal model 
to link the disparate behavioural, metabolic, and gastrointestinal findings in ASD.
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